Oded Har-Even, Esq.
Sullivan & Worcester LLP 1633 Broadway New York, 10019 Tel: 212.660.3000 |
Reut Alfiah, Adv.
Sullivan & Worcester Tel-Aviv
(Har-Even & Co.)
28 HaArba’a St. HaArba’a Towers,
North Tower, 35th Floor
Tel-Aviv, 6473925
T +972.74.758.0480
|
Title of class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Ordinary Shares, no par value
|
SATX
|
NYSE American LLC
|
Warrants to purchase ordinary shares
|
(Title of Class)
|
None
|
(Title of Class)
|
Large Accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
Emerging growth company ☒
|
U.S. GAAP ☐
|
International Financial Reporting Standards as issued by the
International Accounting Standards Board ☒
|
Other ☐ |
PART I |
6 | |
6 | ||
6 | ||
6 | ||
49 | ||
70 | ||
71 | ||
89 | ||
110 | ||
113 | ||
114 | ||
115 | ||
130 | ||
130 | ||
PART II |
131 | |
131 | ||
131 | ||
131 | ||
131 | ||
131 | ||
132 | ||
132 | ||
132 | ||
132 | ||
133 | ||
133 | ||
133 | ||
133 | ||
134 | ||
134 | ||
PART III |
135 | |
135 | ||
135 | ||
136 |
• |
Our performance following the Business Combination; |
• |
Unpredictability in the satellite communications industry; |
• |
The regulatory environment and changes in laws, regulations or policies in the jurisdictions in which we operate; |
• |
Competition in the satellite communications industry, and the failure to introduce new technologies and products in a timely manner
to compete successfully against competitors; |
• |
Failure by us to adjust our supply chain volume due to changing market conditions or failure to estimate its customers’
demand; |
• |
Disruptions in relationships with any one of our key customers; |
• |
Disruptions in relationships with any one of our third-party manufacturers or suppliers; |
• |
Any difficulty selling our products if customers do not design its products into their product offerings; |
• |
Our dependence on winning selection processes and gaining market acceptance of its technologies and products; |
• |
Even if we succeed in winning selection processes for its technologies and products, we may not generate timely or sufficient net
sales or margins from those wins; |
• |
Our ability to execute its strategies, manage growth and maintain its corporate culture as it grows; |
• |
Sustained yield problems or other delays in the manufacturing process of products; |
• |
Changes in the need for capital and the availability of financing and capital to fund these needs; |
• |
Our estimates of our total addressable market and the demand for and pricing of its products and services; |
• |
Our ability to maintain effective internal control over financial reporting; |
• |
Our ability to retain key personnel and to replace such personnel on a timely basis or on acceptable terms; |
• |
Exchange rate fluctuations; |
• |
Changes in interest rates or rates of inflation; |
• |
Legal, regulatory and other proceedings; |
• |
Changes in applicable laws or regulations, or the application thereof on us; |
• |
The results of future financing efforts; |
• |
Our ability to maintain continued listing standards with the NYSE American LLC: |
• |
General market, political and economic conditions in the countries in which we operate including those related to recent unrest and
actual or potential armed conflict in Israel and other parts of the Middle East, such as the Israel-Hamas war; |
• |
Some or all of the expected benefits of the transaction between the Company and MDA will not be achieved; and |
• |
The other matters described in the section titled “Risk Factors”. |
A. |
[Reserved] |
B. |
Capitalization and Indebtedness |
C. |
Reasons for the Offer and Use of Proceeds |
D. |
Risk Factors |
• |
SatixFy has limited capital currently
available and will need to raise additional capital in the future to fund its operations and develop its technology and chips and satellite
communications systems. If SatixFy fails to raise sufficient capital or is unable to do so on favorable or acceptable terms, it might
not be able to make the necessary investments in technology development, its operating results may be harmed, it may have to seek protection
under insolvency laws and may be unable to continue its operations. |
• |
SatixFy is an early stage company with a history of losses, has generated less revenues than its prior projections, and has not demonstrated
a sustained ability to generate predictable revenues or cash flows. If SatixFy does not generate revenue as expected, its financial condition
will be materially and adversely affected. |
• |
SatixFy may face increased risks and costs associated with volatility in labor or component prices or as a result of supply chain
or procurement disruptions, which may adversely affect its operations. |
• |
Obtaining customer contracts may require SatixFy to participate in lengthy competitive selection processes that require it to incur
significant costs. |
• |
Some of SatixFy’s customers may require its chips and satellite communications systems to undergo a demonstration process that
does not assure future sales or customer contracts. |
• |
SatixFy generates a significant percentage of its revenue from certain key customers and anticipates this concentration will continue
for the foreseeable future, and the loss of one or more of its key customers could negatively affect its business and operating results.
|
• |
SatixFy may not be able to continue to develop its technology or develop new technologies for its existing and new satellite communications
systems. |
• |
Deterioration of the financial conditions of SatixFy’s customers could adversely affect its operating results. |
• |
SatixFy operates in a highly competitive industry and may be unsuccessful in effectively competing in the future. |
• |
SatixFy has incurred net losses in each year since inception and may not be able to continue to raise sufficient capital or achieve
or sustain profitability. |
• |
SatixFy may not be able to generate sufficient cash to service its indebtedness. |
• |
SatixFy’s estimates, including market opportunity estimates and growth forecasts, are subject to inherent challenges in measurement
and significant uncertainty, and real or perceived inaccuracies in those metrics and estimates may harm its reputation and negatively
affect its business. |
• |
SatixFy’s results of operations may vary significantly from its expectations or guidance. |
• |
SatixFy may not be able to comply with its contracts with customers, and non-compliance may harm its operations and expose it to
potential third-party claims for damages. |
• |
Loss of key employees and the inability to continuously recruit and retain qualified employees could hurt SatixFy’s competitive
position. |
• |
SatixFy relies on third parties for manufacturing of its products. SatixFy does not have long-term supply contracts with its foundry
or most of its third-party manufacturing vendors, and they may not allocate sufficient capacity to SatixFy at reasonable prices to meet
future demands for its solutions. |
• |
SatixFy’s business is subject to a wide range of laws and regulations, many of which are continuously evolving, and failure
to comply with such laws and regulations could harm its business, financial condition and operating results. |
• |
SatixFy is subject to risks from its international operations. |
• |
SatixFy relies on its intellectual property and proprietary rights and may be unable to adequately obtain, maintain, enforce, defend
or protect its intellectual property and proprietary rights, including against unauthorized use by third parties. |
• |
SatixFy relies on the availability of third-party licenses of intellectual property, and if it fails to comply with its obligations
under such agreements or is unable to extend its existing third- party licenses or enter into new third-party licenses on reasonable terms
or at all, it could have a material adverse effect on its business, operating results and financial condition. |
• |
Defects, errors or other performance problems in SatixFy’s software or hardware, or the third-party software or hardware on
which it relies, could harm SatixFy’s reputation, result in significant costs to SatixFy, impair its ability to sell its systems
and subject it to substantial liability. |
• |
SatixFy is subject to complex and evolving laws, regulations, rules, standards and contractual obligations regarding data privacy
and cybersecurity, which can increase the cost of doing business, compliance risks and potential liability. |
• |
Changes in SatixFy’s effective tax rate may adversely impact its results of operations. |
• |
Exchange rate fluctuations between the U.S. dollar, the British pound, the Euro and other foreign currencies may negatively affect
SatixFy’s future revenues. |
• |
Managing a public company and compliance with regulatory requirements may divert the attention of SatixFy’s senior management
from the day-to-day management of its business. |
• |
An active trading market for SatixFy’s equity securities may not develop or may not be sustained to provide adequate liquidity.
|
• |
The selling shareholders listed in the Registration Statement may be incentivized to sell them under the Registration Statement depending
on the market price of our securities, and sales of a significant number of our securities by such selling shareholders could materially
adversely affect the trading prices of our securities. |
• |
Investors’ rights and responsibilities as SatixFy’s shareholders will be governed by Israeli law, which differs in some
respects from the rights and responsibilities of shareholders of non- Israeli companies. |
• |
The market price of SatixFy’s equity securities may be volatile, and your investment could suffer or decline in value.
|
• |
SatixFy is an “emerging growth company” and avails itself of the reduced disclosure requirements applicable to emerging
growth companies, which could make its equity securities less attractive to investors. |
• |
SatixFy may lose its foreign private issuer status in the future, which could result in significant additional costs and expenses.
|
• |
Future sales or other issuances of our securities could depress the market price for our securities. |
• |
Failure to meet NYSE’s continued listing requirements could result in the delisting of our Ordinary Shares, negatively impact
the price of our Ordinary Shares and negatively impact our ability to raise additional capital. |
• |
the effects of catastrophic and other disruptive events at our customers’ operational sites or targeted markets including,
but not limited to, natural disasters, telecommunications failures, geopolitical instability caused by international conflict, including
the Russia-Ukraine and Israel-Hamas wars, cyber-attacks, terrorist attacks, pandemics, epidemics or other outbreaks of infectious disease,
and breaches of security or loss of critical data; |
• |
increased costs associated with potential disruptions to our or our customers’ supply chain and other manufacturing and production
operations; |
• |
the deterioration of our customers’ financial condition; |
• |
delays and project cancellations as a result of design flaws in the chips and communications systems developed by us or our customers;
|
• |
the inability of our customers to dedicate the resources necessary to promote and commercialize their products; |
• |
the inability of our customers to adapt to changing technological demands resulting in their products becoming obsolete; and
|
• |
the failure of our satellite communications systems or our customers’ products to achieve market success and gain market acceptance.
|
• |
our ability to anticipate the needs of the market for new generations of satellite communications digital chip technology;
|
• |
our ability to continue funding and to maintain our current research and development activities, particularly the development of
enhancements to our chips and systems; |
• |
our ability to successfully integrate our advanced technologies and system design architectures into satellite communications systems
that are compatible with our customers’ infrastructure; |
• |
our ability to develop and introduce timely, qualified
and on-budget new satellite communications systems or chips that meet the market’s technological requirements; |
• |
our ability to establish close working relationships with our customers and to have them integrate our satellite communications systems
in their design of new communications systems; |
• |
our ability to maintain intellectual properties rights, whether proprietary or third-party, that are necessary to our research and
development activities, such as chip development software; |
• |
our ability to gain access to the proprietary waveforms that potential customers utilize; and |
• |
our ability to obtain funding for continuing our technology and product development. |
• |
our ability to timely introduce to the market our current chips and satellite communications systems; |
• |
our ability to develop new chips and satellite communications systems that respond to customer requirements; |
• |
changes in cost estimates and cost overruns associated with our development projects; |
• |
changes in demand for, and market conditions of, our chips and satellite communications systems; |
• |
the ability of third-party foundries and other third-party suppliers to manufacture, assemble and test our chips and satellite communications
systems in a timely and cost-effective manner; |
• |
the discovery of defects or errors in our hardware or software after delivery to customers; |
• |
our ability to achieve cost savings and improve yields and margins on our new and existing products; |
• |
our ability to utilize our capacity efficiently or to adjust such capacity in response to customer demand; |
• |
our ability to realize the expected benefits of any acquisitions or strategic investments; |
• |
business, political, geopolitical and macroeconomic changes, including the Russia-Ukraine and Israel-Hamas wars. trade disputes,
the imposition of tariffs or sanctions, inflation trends and downturns in the semiconductor and the satellite communications industries
and the overall global economy; and |
• |
changes in consumer confidence caused by many factors, including changes in interest rates, credit markets, expectations for inflation,
unemployment levels, and energy or other commodity prices. |
• |
hire and retain qualified professionals; |
• |
continue to develop leaders for key business units and functions; and |
• |
train and motivate our employee base. |
• |
negative economic developments in economies around the world and the instability of governments; |
• |
social and political instability in Israel, including the Israel-Hamas war, and in the other countries in which we operate;
|
• |
pandemics or national and international environmental, nuclear or other disasters, which may adversely affect our workforce, as well
as our local suppliers and customers; |
• |
adverse changes in governmental policies, especially those affecting trade and investment; |
• |
foreign currency exchange, in particular with respect to the U.S. dollar, the Euro, the British pound sterling, the Israeli Shekel,
and transfer restrictions, in particular in Russia and China; |
• |
global and local economic, social and political conditions and uncertainty; |
• |
formal or informal imposition of export, import or doing-business regulations, including trade sanctions, tariffs and other related
restrictions; |
• |
compliance with laws and regulations that differ among jurisdictions, including those covering taxes, intellectual property ownership
and infringement, export control regulations, anti- corruption and anti-bribery, antitrust and competition, data privacy, cybersecurity
and environment, health and safety; |
• |
labor market conditions and workers’ rights affecting our operations; and |
• |
occurrences of geopolitical crises such as terrorist activity, armed conflict, civil or military unrest or political instability,
which may disrupt our operations — for example, conflicts in Asia implicating the global semi-conductor supply-chain, such as conflicts
between Taiwan and China, the war between Russia and Ukraine, the war between Israel and Hamas, the tense relations between the U.S. and
China, could lead to regional and/or global instability, as well as adversely affect supply chains as well as commodity and other financial
markets or economic conditions. The U.S., European Union (the “EU”), the United Kingdom, Switzerland and other countries have
imposed, and may further impose, financial and economic sanctions and export controls targeting certain Russian entities and/or individuals,
and we, or our customers, may face restrictions on engaging with certain businesses due to any current or impending sanctions and laws,
which could adversely affect our business; and |
• |
threats that our operations or property could be subject to nationalization and expropriation. |
• |
changes in our overall profitability and the amount of profit determined to be earned and taxed in jurisdictions with differing statutory
tax rates; |
• |
the resolution of issues arising from tax audits with various tax authorities; |
• |
the impact of transfer pricing policies; |
• |
changes in the valuation of either our gross deferred tax assets or gross deferred tax liabilities; |
• |
changes in expenses not deductible for tax purposes; |
• |
changes in available tax credits; and |
• |
changes in tax laws or the interpretation of such tax laws, and changes in generally accepted accounting principles. |
• |
the book-building process undertaken by underwriters that helps to inform efficient price discovery with respect to opening trades
of newly listed securities; |
• |
underwriter support to help stabilize, maintain or affect the public price of the new issue immediately after listing; and
|
• |
underwriter due diligence review of the offering and potential liability for material misstatements or omissions of fact in a prospectus
used in connection with the securities being offered or for statements made by its securities analysts or other personnel. |
• |
a limited availability of market quotations for the warrants; |
• |
reduced liquidity for the warrants; |
• |
a determination that our warrants are a “penny stock” which will require brokers trading in our warrants to adhere to
more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Warrants; and
|
• |
the risk that market makers that initially make a market in our unexchanged warrants eventually cease to do so. |
• |
the rescheduling, increase, reduction or cancellation of significant customer orders; |
• |
the timing of customer qualification of our products and commencement of volume sales by our customers of systems that include our
products; |
• |
the timing and amount of research and development and sales and marketing expenditures; |
• |
the rate at which our present and future customers and end users adopt our technologies in our target end markets; |
• |
the timing and success of the introduction of new products and technologies by us and our competitors, and the acceptance of our
new products by our customers; |
• |
our ability to anticipate changing customer product requirements; |
• |
our gain or loss of one or more key customers; |
• |
the availability, cost and quality of materials and components that we purchase from third-party vendors and any problems or delays
in the manufacturing, testing or delivery of our products; |
• |
the availability of production capacity at our third-party facilities or other third-party subcontractors and other interruptions
in the supply chain, including as a result of materials shortages, bankruptcies or other causes; |
• |
supply constraints for and changes in the cost of the other components incorporated into our customers’ products; |
• |
our ability to reduce the manufacturing costs of our products; |
• |
fluctuations in manufacturing yields; |
• |
the changes in our product mix or customer mix; |
• |
the timing of expenses related to the acquisition of technologies or businesses; |
• |
product rates of return or price concessions in excess of those expected or forecasted; |
• |
the emergence of new industry standards; |
• |
product obsolescence; |
• |
unexpected inventory write-downs or write-offs; |
• |
costs associated with litigation over intellectual property rights and other litigation; |
• |
the length and unpredictability of the purchasing and budgeting cycles of our customers; |
• |
loss of key personnel or the inability to attract qualified engineers; |
• |
the quality of our products and any remediation costs; |
• |
adverse changes in economic conditions in the various markets where we or our customers have operations; |
• |
the general industry conditions and seasonal patterns in our target end markets, particularly the satellite communications market;
|
• |
other conditions affecting the timing of customer orders or our ability to fill orders of customers subject to export control or
economic sanctions; and |
• |
geopolitical events, such as war, threat of war or terrorist actions, including the current wars between Russia-Ukraine and Israel-Hamas,
or the occurrence of pandemics, epidemics or other outbreaks of disease, including the COVID-19 pandemic, or natural disasters, and the
impact of these events on the factors set forth above. |
• |
the Israeli Companies Law regulates mergers and requires that a tender offer be effected when one or more shareholders propose to
purchase shares that would result in it or them owning more than a specified percentage of shares in a company; |
• |
the Israeli Companies Law requires special approvals for certain transactions involving directors, officers or significant shareholders
and regulates other matters that may be relevant to these types of transactions; |
• |
the Israeli Companies Law does not provide for shareholder action by written consent for public companies, thereby requiring all
shareholder actions to be taken at a general meeting of shareholders; |
• |
our amended and restated articles of association divide our directors into three classes, each of which is elected once every three
years; |
• |
an amendment to our amended and restated articles of association generally requires, in addition to the approval of our board of
directors, a vote of the holders of a majority of our outstanding ordinary shares entitled to vote present and voting on the matter at
a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision
empowering our board of directors to determine the size of the board, the provision dividing our directors into three classes, the provision
that sets forth the procedures and the requirements that must be met in order for a shareholder to require the Company to include a matter
on the agenda for a general meeting of the shareholders, the provisions relating to the election and removal of members of our board of
directors and empowering our board of directors to fill vacancies on the board, requires, in addition to the approval of our board of
directors, a vote of the holders of 66-2⁄3% of our outstanding ordinary shares entitled to vote at a general meeting; |
• |
our amended and restated articles of association do not permit a director to be removed except by a vote of the holders of at least
66-2⁄3% of our outstanding shares entitled to vote at a general meeting of shareholders; and |
• |
our amended and restated articles of association provide that director vacancies may be filled by our board of directors. |
• |
sales of a significant number of our securities, including those which we plan to register in connection with the Equity Line of
Credit and by the selling securityholders under our resale registration statement on Form F-1 (Registration No. 333-268510), or that we
may in the future register for sale or for resale on behalf of our securityholders, could materially adversely affect the trading prices
of our securities; |
• |
the realization of any of the risk factors presented in this Annual Report; |
• |
actual or anticipated differences in our estimates, or in the estimates of analysts, for our revenues, earnings, results of operations,
level of indebtedness, liquidity or financial condition; |
• |
failure to comply with the requirements of the NYSE; |
• |
failure to comply with the Sarbanes-Oxley Act or other laws or regulations; |
• |
variance in our financial performance from the expectations of market analysts; |
• |
announcements by us or our competitors of significant business developments, changes in service provider relationships, acquisitions
or expansion plans; |
• |
changes in the prices of our products and services; |
• |
commencement of, or involvement in, litigation involving us; |
• |
future issuances, sales, repurchases or anticipated issuances, sales, resales or repurchases, of our securities including due to
the expiration of contractual lock-up agreements; |
• |
publication of research reports about us; |
• |
failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates by any securities analysts
who follow us or our failure to meet these estimates or the expectations of investors; |
• |
new laws, regulations, subsidies, or credits or new interpretations of existing laws applicable to us; |
• |
market conditions in our industry; |
• |
changes in key personnel; |
• |
speculation in the press or investment community; |
• |
changes in the estimation of the future size and growth rate of our markets; |
• |
broad disruptions in the financial markets, including sudden disruptions in the credit markets; |
• |
actual, potential or perceived control, accounting or reporting problems; |
• |
changes in accounting principles, policies and guidelines; and |
• |
other events or factors, including those resulting from infectious diseases, health epidemics and pandemics, natural disasters, war,
including the current wars between Russia-Ukraine and Israel-Hamas, acts of terrorism or responses to these events. |
• |
the last day of the fiscal year during which our total annual revenue equals or exceeds $1.235 billion (subject to adjustment for
inflation); |
• |
the last day of the fiscal year following the fifth anniversary of our initial registered offering; |
• |
the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; or |
• |
the date on which we are deemed to be a “large accelerated filer” under the Exchange Act. |
A. |
History and Development of the Company |
B. |
Business Overview |
• |
The satellite payload, which is the system
integrated to the satellite platform that provides in-space data receiving, processing and transmitting capabilities. |
• |
The user terminal, which is the system on
the ground (or aircraft, in the case of IFC), comprised of an antenna and modem, that digitally links to the satellite payload and provides
data receiving, processing and transmitting capabilities. |
• |
The hub, which is the system that enables
the network operator to control and manage its communication network and the interaction between the satellite payload and the ground
terminal. |
• |
Modems. We have developed our modems based on our proprietary SX-3000 and SX-3099 Very Small
Aperture Terminal (“VSAT”) chips, a part of our ASIC technology and one of the base building blocks for all our terminal products.
We produce modem modules designed to bring the fastest performance available today in a compact form factor and with low power. All of
our modems are designed for easy integration with our customers’ hardware, and software solutions and are available for a variety
of applications. Our modems are designed to natively support the entire DVB-RCS2 / DVB-S2X industry standards as well as a complete SDR
for any other waveform, to ensure maximum flexibility and relevance to our customer base. These industry standards are intended to ensure
that systems that utilize them perform with better efficiency, more throughput and better network reliability. We were directly involved
in writing the DVB-S2X standard which is based in part on our technology and patents. |
• |
Antennas. We offer a line of advanced ESMA products based on our proprietary BEAT and PRIME
ASIC chip technologies for both ground and Aero/IFC terminal connectivity. |
• |
Cutting-Edge Chips. We believe we are positioned to be a leading provider of satellite communications
systems for the next generation of satellites. Our modem chips have the ability to split data for retransmission and combine received
data from nearby satellites or ground hubs efficiently and quickly. Our chip technology enables us to develop communications systems that
are high performing, low weight, energy efficient and sized to be compatible for a wide array of applications and satellite technologies.
|
• |
Advanced Antennas and Modems. Our technology in the field of multibeam management, transmission
and beamforming and hopping, based on our advanced chips, introduces a new and advanced generation of flat electronic antennas that will
be critical to enabling user terminals to track multiple LEO satellites at a time. Our ESMA chips enable efficiency, modularity and scalability
to support multibeam and high data rates. We are designing efficient and innovative digital interfaces for our modems to enable them to
handle numerous transmission and reception beams, which will be necessary for LEO satellite networks. |
• |
Tailor Made. We have the ability to design and present customers with customized solutions
using our whole family of highly flexible chips and modules that integrate with their planned or existing systems, and which can be tailored
to meet their requirements. We believe that providing optimized cost-effective solutions, in an era when satellite technology is rapidly
evolving, is important for positioning us at the technological forefront of the market and securing relationships with leading communications
providers. |
• |
End-to-End Solutions. Our development team manages the entire product development life cycle,
beginning with the characterization stage, through to the design and third-party manufacture of the chips, integration of the chips within
communications systems, testing of the systems and culminating with delivery and the provision of operational support to the customer.
The solutions we provide enable customers to enjoy an efficient and continuous process for the development of their systems with a single
supplier and single point of contact throughout the entire development and implementation process. We develop the chips, design the systems
that integrate the chips, write the software needed to operate the chips and manage integration of the various components into a single,
cohesive satellite communications systems that fits our customers’ needs. |
• |
Superior Technology Leading to Superior Performance. We believe we are a technology and product
leader in the growing satellite communications industry, as evidenced by our innovative technologies such as the digital beamforming and
the beam-hopping chip technology. Our chips are designed to power our satellite communications systems, which in turn enhance satellite
communications capabilities, including on-board processing capabilities driven by channel switching and flexibility. |
• |
Tailor-Made Innovation of Next-Generation Satellite Communications Technology. Our SDR modem
and antenna chips are designed to be tailored and optimized to meet the technical requirements of our customers in their respective end
markets without the traditional expense of developing bespoke chips each time. This is a significant differentiator from, and combined
with the over $243 million we have invested in research and development, creates significant barriers to entry for, our competitors. Our
communications systems are also capable of being tailored to our customers’ needs, while promoting efficiency through a common chip
set across the entire satellite communications value chain. In many cases, our close relationships with our customers in the design stage
and our deep engineering expertise, position us in a limited group of satellite communications system developers capable of providing
the necessary solutions to our customers. We believe these close working relationships, coupled with our proprietary technology and experience,
help our customers achieve higher throughput capacity and better integration of all key components of the satellite communications system,
while providing advantages in terms of lower weight and power consumption. We believe our solution enables overall lower systems costs
relative to our principal competitors. |
• |
Silicon Enabled SWaP-C. The use of silicon-based technologies in our satellite communications
chips and systems is key to achieving the industry’s goal of producing systems that are smaller in size and lower in weight, power
consumption and cost. |
• |
Higher Reliability, Lower Maintenance and Faster Installation. The use of silicon in our
antenna systems makes them more reliable than the mechanical antennas available in the market due to fewer moving parts, fewer failure
points and faster installation time of our antennas. We have designed our antenna systems to be easier to install and require less maintenance
than systems using mechanical elements with complex packaging. |
• |
End-to-End Capabilities Promoting Long-term Customer Relationships. We often cover the entire
life cycle of the systems we deliver to our customers, from defining specifications according to our customers’ requirements, to
designing or redesigning the chips, to oversight of the assembly of the final product and the subsequent delivery of custom-tailored products
to the customer. We believe that our participation in serving the entire life cycle of the customer’s satellite communications system
promotes long-term customer relationships, as once our tailor-made systems are integrated in a customer’s satellite constellation
or the ground communications infrastructure, the costs of switching to a different provider of satellite communications systems could
often be substantial. |
• |
Proven Management Team. Our founders and executive management team have extensive experience
in effectively guiding companies through various industry cycles and technology transitions. We have recently strengthened our leadership
with the joining of Mr. Nir Barkan as a Chief Executive Officer as of June 1, 2023 and the addition of Itzik Ben Bassat as our Chief Operating
Officer as of February 12, 2023. Mr. Nir brings extensive experience of leading high tech technologies and products companies, including
Curvalux, Orbit and Texas Instruments. Mr. Yoav Leibovitch, our Executive Chairman of the Board, has vast experience in leading the financial
strategizing and investor relations of public companies. Our management team provides us with steady, reliable leadership, uniquely capable
of identifying strong investments, executing through change, and maintaining stability during market uncertainty. |
• |
Strengthen our Technology Leadership. We believe that our success thus far is largely attributable
to our digital silicon chip design expertise. We aim to leverage our design expertise to continue developing high-performing chips and
systems that are smaller, lighter, have lower power consumption and a lower cost, while continuing to invest in research and development
to maintain our technology leadership in this market. |
• |
Capitalize on LEO and IFC Market Opportunities. The satellite communications market presents
significant opportunities for innovative solutions. The introduction of the new LEO satellite constellations creates the need for smaller
satellite communications systems that can handle higher speeds, larger capacity and operate with lower power consumption. Our modem and
antenna chips, as well as our satellite payload, user terminal and hub systems were developed to meet the new technological needs of the
LEO satellite constellations. New opportunities in the Aero/IFC market are emerging as the demand for “home-like” broadband
connectivity on commercial flights increases, creating the need for IFC systems that can deliver fast and reliable connectivity. By developing
our chips and systems to meet new market opportunities, we intend to expand the deployment of our next generation chips and systems.
|
• |
Leverage and Expand our Existing Customer Base. We intend to continue to develop long-term,
collaborative relationships with top tier customers who are regarded as leaders in their respective markets. We intend to continue to
focus on sales to these customers and build on our relationships with them to define and enhance our product roadmap and expand our scope
of business with them. Engaging with market leaders will also enable us to participate in emerging technology trends and new industry
standards. |
• |
Attract and Retain Top Talent. We are committed to recruiting and retaining talented professionals
with proven expertise in the design, development, marketing and sales of satellite communications chips and systems. We believe we have
assembled a high-quality global multinational team in all the areas of expertise required for a leading satellite communications company.
We believe that our ability to attract the best engineers is a critical component of our future growth and success. |
• |
Expand our Global Presence. We intend to continue strengthening our relationships with our
existing customers, while also planning for increased demand as our brand recognition grows. We intend to continue expanding our presence
worldwide as we grow in our market to serve the needs of clients in additional geographies and tap into talent pools from international
markets. |
• |
Vertical Integration- As part of our go-to-market strategy, we are working on vertical integration with leading market players. For
example, In August 2023, we announced a $60 million transaction with MDA Ltd. (“MDA”) (TSX: MDA), a leading provider of advanced
technology and services to the rapidly expanding global space industry. The MDA Agreement establishes cooperation between the companies
to utilize our digital payload chip-based technology to advanced digital satellite payloads, which the parties believe to be unparalleled
in today’s market, and is expected to open up our solutions to broader markets as well as new customers. The MDA Agreement is an
example of our strategy towards vertical integration for the space payload business. |
D. |
Organizational Structure |
Year Ended December 31 |
||||||||
2023 |
2022 |
|||||||
(U.S.$ in thousands, except percentages) |
||||||||
Revenues |
$ |
10,730 |
$ |
10,626 |
||||
Gross profit |
$ |
4,792 |
$ |
6,128 |
||||
Gross margin |
45 |
% |
58 |
% | ||||
Net loss |
$ |
(29,715 |
) |
$ |
(397,789 |
)(*) |
A. |
Results of Operations |
|
Year Ended
December 31, |
|||||||||||||||
|
2023
|
2022
|
Change
|
% |
||||||||||||
|
(U.S.$ in thousands,
except percentages) |
|||||||||||||||
Revenues:
|
||||||||||||||||
Development services and preproduction |
$ |
8,249 |
$ |
10,081 |
$ |
(1,832 |
) |
(18 |
)% | |||||||
Sale of products |
2,481 |
545 |
1,936 |
355 |
% | |||||||||||
Total revenues |
$ |
10,730 |
$ |
10,626 |
$ |
104 |
1 |
% | ||||||||
Cost of sales and
services: |
||||||||||||||||
Development services and preproduction |
4,930 |
4,166 |
764 |
18 |
% | |||||||||||
Sale of products |
1,008 |
332 |
676 |
204 |
% | |||||||||||
Total cost of sales and services |
5,938 |
4,498 |
1,440 |
32 |
% | |||||||||||
|
||||||||||||||||
Gross profit |
$ |
4,792 |
$ |
6,128 |
$ |
(1,336 |
) |
(22 |
)% | |||||||
Research and development expenses |
29,126 |
16,842 |
12,284 |
73 |
% | |||||||||||
Selling and marketing expenses |
2,866 |
2,335 |
531 |
23 |
% | |||||||||||
General and administrative expenses |
14,561 |
9,249 |
5,312 |
57 |
% | |||||||||||
Loss from operations |
$ |
(41,761 |
) |
$ |
(22,298 |
) |
$ |
19,463 |
87 |
% | ||||||
Finance Income |
83 |
17 |
66 |
388 |
% | |||||||||||
Finance Expenses |
(12,129 |
) |
(9,919 |
) |
2,210 |
22 |
% | |||||||||
Derivatives Revaluation |
(17,217 |
) |
(37,377 |
) |
(20,160 |
) |
(54 |
%) | ||||||||
Other Income |
41,657 |
5,474 |
36,183 |
661 |
% | |||||||||||
Listing Expenses |
- |
(333,326 |
) |
(333,326 |
) |
(100 |
)% | |||||||||
Share in the loss of a company accounted by equity
method, net |
(226 |
) |
(360 |
) |
(134 |
) |
(37 |
)% | ||||||||
|
||||||||||||||||
Loss before income taxes
|
$ |
(29,593 |
) |
$ |
(397,789 |
) |
$ |
(368,196 |
) |
(93 |
)% | |||||
Tax expenses |
(122 |
) |
- |
122 |
100 |
% | ||||||||||
Loss for the period (1) |
$ |
(29,715 |
) |
$ |
(397,789 |
) |
$ |
(368,074 |
) |
(93 |
)% |
(1) |
Net loss for the year ended December 31, 2022 reflects the impact of a $333 million non-recurring, listing expense, of which $318
million was a non-cash expense due to the application of IFRS 2 (Share-based Payments) and a $37.4 million non-cash finance expense reflecting
the revaluation of a derivative contract relating to the transactions under the Forward Purchase Agreement. Neither of the aforementioned
non-cash expenses had any impact on our income tax expense or benefit for the year ended December 31, 2022 or on our deferred tax assets
or liabilities as of that date. See 25 to our consolidated financial statements included elsewhere in this Annual Report for more information.
|
B. |
Liquidity and Capital Resources |
For the year ended December 31 (in thousands of USD) |
||||||||
2023
|
2022
|
|||||||
Cash Flow Data: |
||||||||
Net cash used in operating activities |
(24,635 |
) |
(31,480 |
) | ||||
Net cash used in investing activities |
17,341 |
(582 |
) | |||||
Net cash provided by financing activities |
9,114 |
40,523 |
||||||
Increase (decrease) in cash and cash equivalents
|
1,820 |
8,461 |
||||||
Cash and cash equivalents balance at the beginning
of the year |
11,934 |
3,854 |
||||||
Effect of changes in foreign exchange rates on cash
and cash equivalents |
225 |
(381 |
) | |||||
Cash and cash equivalents balance at the end of the
period |
13,979 |
11,934 |
C. |
Research and Development, Patents and Licenses |
D. |
Trend Information |
E. |
Critical Accounting Policies and Estimates |
• |
the product is technically and commercially feasible; |
• |
we intend to complete the product so that it will be available for use or sale; |
• |
we have the ability to use or sell the product; |
• |
we have the technical, financial and other resources to complete the development and to use or sell the product; |
• |
we can demonstrate the probability that the product will generate future economic benefits; and |
• |
we are able to reliably measure the expenditure attributable to the product during its development. |
A. |
Directors and Senior Management |
Name |
Age |
Position | ||
Yoav Leibovitch(8)
|
66 |
Executive Chairman of the Board of Directors | ||
Nir Barkan |
45 |
Acting Chief Executive Officer | ||
Oren Harari |
49 |
Interim Chief Financial Officer | ||
Doron Rainish |
68 |
Chief Technology Officer | ||
Divaydeep Sikri |
45 |
Vice President and Chief Engineer | ||
Stephane Zohar |
57 |
Executive Vice President — VLSI | ||
Itzik Ben Bassat |
55 |
Chief Operating Officer | ||
Mary P. Cotton((1)2)((3)(4)(
(7) |
66 |
Director | ||
Yair Shamir(6) |
78 |
Director | ||
David L. Willetts(7)
|
68 |
Director | ||
Richard C. Davis(8)
|
58 |
Director | ||
Moshe Eisenberg(1)(2)(3)(4)(5)
|
57 |
Director | ||
Yoram Stettiner(1)(2)((3)(4)(5)
|
66 |
Director |
Executive Officers |
(1) |
Member of the Compensation Committee |
(2) |
Member of the Audit Committee |
(3) |
Independent Director (as defined under Israeli law) |
(4) |
Independent Director (as defined under NYSE American LLC Company Guide Manual Section 803(A)(2), or NYSE American Section 803(A)(2))
|
(5) |
External director, if required under the Companies law |
(6) |
Class I directors hold office until the annual general
meeting to be held in 2026 and until their successors shall have been elected and qualified |
(7) |
Class II directors hold office until the annual general
meeting to be held in 2024 and until their successors shall have been elected and qualified |
(8) |
Class III directors hold office until the annual general
meeting to be held in 2025 and until their successors shall have been elected and qualified |
B. |
Compensation |
Name and Position of
Director or Officer |
Base Salary or
Other Payment (1) |
Value of
Social Benefits (2) |
Bonuses |
Value of
Equity- Based Compensation
Granted (3) |
All Other
Compensation (4) |
Total |
||||||||||||||||||
Yoav Leibovitch |
1,200,000 |
0 |
1,000,000 |
38,309 |
0 |
2,238,309 |
||||||||||||||||||
Nir Barkan |
207,356 |
60,073 |
195,768 |
128,875 |
0 |
592,072 |
||||||||||||||||||
Oren Harari |
229,942 |
64,384 |
191,538 |
73,590 |
0 |
559,454 |
||||||||||||||||||
Itzik Ben Bassat |
220,223 |
61,663 |
110,284 |
279,516 |
0 |
671,686 |
||||||||||||||||||
Simona Gat (5) |
605,000 |
0 |
38,309 |
38,309 |
0 |
643,309 |
(1) |
“Base Salary or Other Payment” means the aggregate yearly gross monthly salaries or other payments with respect to the
Company’s executive officers and members of the board of directors for the year 2023. |
(2) |
“Social Benefits” include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
may include, to the extent applicable to the relevant officers, payments, contributions and/or allocations for savings funds (e.g., Managers’
Life Insurance Policy), education funds (referred to in Hebrew as "keren hishtalmut"), pension, severance, vacation, car or car allowance,
rent for relocated officers, medical insurances and benefits, risk insurance (e.g., life, disability, accident), telephone, convalescence
pay, payments for social security, tax gross-up payments and other benefits and perquisites. |
(3) |
Represents the equity-based compensation expenses recorded in the Company's consolidated financial statements for the year ended
December 31, 2023, calculated in accordance with accounting guidance for equity-based compensation. For a discussion on the assumptions
used in reaching this valuation, see Note 18 to our consolidated financial statements included elsewhere in this Annual Report.
|
(4) |
“All Other Compensation” includes, among other things, car-related expenses (including tax gross-up), communication expenses,
basic health insurance, and holiday presents. |
(5) |
Ms. Gat resigned from her positions as President of SatixFy, the CEO and a director of Satixfy UK Limited, and a director of Satixfy
Bulgaria effective April 30, 3023. |
• |
information on the business advisability of a given action brought for the office holder’s approval or performed by virtue
of the office holder’s position; and |
• |
all other important information pertaining to such action. |
• |
refrain from any act involving a conflict of interest between the performance of the office holder’s duties in the company
and the office holder’s other duties or personal affairs; |
• |
refrain from any activity that is competitive with the business of the company; |
• |
refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for the office holder
or others; and |
• |
disclose to the company any information or documents relating to the company’s affairs which the office holder received as
a result of the office holder’s position. |
• |
an amendment to the company’s articles of association; |
• |
an increase of the company’s authorized share capital; |
• |
a merger; or |
• |
interested party transactions that require shareholder approval. |
C. |
Board Practices |
• |
such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not
have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with
a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested majority; or
|
• |
the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest in the election
of the external director against the election of the external director does not exceed 2% of the aggregate voting rights in the company.
|
• |
his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company’s
voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling,
disinterested shareholders voting for such re-election exceeds 2% of the aggregate voting rights in the company, subject to additional
restrictions set forth in the Israeli Companies Law with respect to affiliations of external director nominees; |
• |
the external director proposed his or her own nomination, and such nomination was approved in accordance with the requirements described
in the paragraph above; or |
• |
his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders
by the same majority required for the initial election of an external director (as described above). |
• |
an employment relationship; |
• |
a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships);
|
• |
control; and |
• |
service as an office holder, excluding service as a director in a private company prior to the initial public offering of its shares
if such director was appointed as a director of the private company in order to serve as an external director following the initial public
offering. |
• |
at least a majority of the shares of non-controlling shareholders or shareholders that do not have a personal interest in the approval
voted at the meeting are voted in favor (disregarding abstentions); or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such appointment
voting against such appointment does not exceed 2% of the aggregate voting rights in the company. |
• |
he or she meets the qualifications for being appointed as an external director, except for the requirement (i) that the director
be an Israeli resident (which does not apply to companies such as ours whose securities have been offered outside of Israel or are listed
for trading outside of Israel) and (ii) for accounting and financial expertise or professional qualifications; and |
• |
he or she has not served as a director of the company for a period exceeding nine consecutive years. For this purpose, a break of
less than two years in his or her service as a director shall not be deemed to interrupt the continuity of the service. A majority of
our audit committee (each, as identified in the second paragraph under “— Listing Requirements”
below) are external directors under the Israeli Companies Law, thereby fulfilling the foregoing Israeli law requirement for the composition
of the audit committee. |
• |
retaining and terminating our independent auditors, subject to ratification by the board of directors and by the shareholders;
|
• |
pre-approving audit and non-audit services to be provided by the independent auditors and related fees and terms; |
• |
overseeing the accounting and financial reporting processes of our company; |
• |
managing audits of our financial statements; |
• |
preparing all reports as may be required of an audit committee under the rules and regulations promulgated under the Exchange Act;
|
• |
reviewing with management and our independent auditor our annual and quarterly financial statements prior to publication, filing,
or submission to the SEC; |
• |
recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor’s engagement
fees and terms, in accordance with the Israeli Companies Law as well as approving the yearly or periodic work plan proposed by the internal
auditor; |
• |
reviewing with counsel, as deemed necessary, legal and regulatory matters that may have a material impact on the financial statements;
|
• |
identifying irregularities in our business administration, including by consulting with the internal auditor (if any) or with the
independent auditor, and suggesting corrective measures to the board of directors; |
• |
reviewing policies and procedures with respect to transactions (other than transactions related to the compensation or terms of services)
between the company and officers and directors, or affiliates of officers or directors, or transactions that are not in the ordinary course
of the Company’s business and deciding whether to approve such acts and transactions if so required under the Israeli Companies
Law; and |
• |
establishing procedures for the handling of employees’ complaints as to the management of our business and the protection to
be provided to such employees. |
• |
recommending to the board of directors with respect to the approval of the compensation policy for “office holders” (a
term used under the Israeli Companies Law, which essentially means directors and executive officers) and, once every three years, regarding
any extensions to a compensation policy that has been in effect for a period of more than three years; |
• |
reviewing the implementation of the compensation policy and periodically recommending to the board of directors with respect to any
amendments or updates of the compensation plan; |
• |
resolving whether or not to approve arrangements with respect to the terms of office and employment of office holders; and
|
• |
exempting, under certain circumstances, from the requirement of approval by the general meeting of shareholders, transactions with
a candidate to serve as the chief executive officer of SatixFy. |
• |
recommending to our board for its approval a compensation policy in accordance with the requirements of the Israeli Companies Law
as well as other compensation policies, incentive- based compensation plans and equity-based compensation plans, and overseeing the development
and implementation of such policies and recommending to our board of directors any amendments or modifications the committee deems appropriate,
including as required under the Israeli Companies Law; |
• |
reviewing and approving the granting of options and other incentive awards to our Chief Executive Officer and other executive officers,
including reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other
executive officers, including evaluating their performance in light of such goals and objectives; |
• |
approving and exempting certain transactions regarding office holders’ compensation pursuant to the Israeli Companies Law
|
• |
administer our clawback policy; and |
• |
administering our equity-based compensation plans, including without limitation, approving the adoption of such plans, amending and
interpreting such plans and the awards and agreements issued pursuant thereto, and making awards to eligible persons under the plans and
determining the terms of such awards. |
• |
such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and do not have
a personal interest in such compensation policy and who are present and voting (excluding abstentions); or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation
policy and who vote against the policy, does not exceed 2% of the company’s aggregate voting rights. |
• |
the education, skills, experience, expertise and accomplishments of the relevant office holder; |
• |
the office holder’s position, responsibilities and prior compensation agreements with him or her; |
• |
the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the
company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost,
the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in
the company; |
• |
if the terms of employment include variable components — the possibility of reducing variable components at the discretion
of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and
|
• |
if the terms of employment include severance compensation — the term of employment or office of the office holder, the terms
of his or her compensation during such period, the company’s performance during such period, his or her individual contribution
to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the
company. |
• |
with regard to variable components of compensation: |
• |
with the exception of office holders who report directly to the chief executive officer, provisions determining the variable components
on the basis of long-term performance and on measurable criteria; however, the company may determine that an immaterial part of the variable
components of the compensation package of an office holder shall be awarded based on non-measurable criteria, if such amount is not higher
than three monthly salaries per annum, while taking into account such office holder’s contribution to the company; and |
• |
the ratio between variable and fixed components, as well as the limit on the values of variable components at the time of their grant.
|
• |
a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation
policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to be discovered
to be wrong, and such information was restated in the company’s financial statements; |
• |
the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable,
while taking into consideration long-term incentives; and |
• |
a limit on retirement grants. |
• |
at least a majority of the shares of non-controlling shareholders or shareholders that do not have a personal interest in the approval
voted at the meeting are voted in favor (disregarding abstentions); or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such appointment
voting against the inconsistent provisions of the compensation package does not exceed 2% of the aggregate voting rights in the company.
|
D. |
Employees |
E. |
Share Ownership |
F. |
Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation. |
A. |
Major Shareholders |
• |
each person who is the beneficial owner of more than 5% of the outstanding shares of any series of our voting ordinary shares;
|
• |
each of our then-current executive officers and directors;
and |
• |
all executive officers and directors of the Company,
as a group. |
(1) |
Consists of 5,673,846 SatixFy Ordinary Shares, including 500,000 Price Adjustment Shares, and 3,765,096 SatixFy Ordinary Shares underlying
the SatixFy Warrants. Richard C. Davis shares voting and investment control over shares held by the Sponsor by virtue of his shared control
of the Sponsor. By virtue of this relationship, Richard C. Davis may be deemed to share beneficial ownership of the securities held of
record of the Sponsor. Richard C. Davis has disclaimed beneficial ownership of the shares, except to the extent of his pecuniary interest
therein, if any. The business address for Endurance Antarctica Partners, LLC is 200 Park Avenue, 32nd Floor New York, NY 10166.
|
(2) |
Ms. Gat resigned from her positions as President of SatixFy, the CEO and a director of Satixfy UK Limited, and a director of Satixfy
Bulgaria, effective April 30, 2023. |
(3) |
Consists of 16,186,297 SatixFy Ordinary Shares held directly.
Ms. Simona Gat is one of SatixFy’s founders. Ms. Simona Gat’s holdings include 9,000,000 Price Adjustment Shares, and 1,403,981
SatixFy Ordinary Shares underlying options to acquire SatixFy Ordinary Shares exercisable within 60 days of March 28, 2024 |
(4) |
The business address for each of the directors and officers of SatixFy is 2 Hamada St., Rehovot 670315, Israel. |
(5) |
Consists of 1,153,679 SatixFy Ordinary Shares held directly and
179,513 SatixFy Ordinary Shares underlying options to acquire SatixFy Ordinary Shares exercisable within 60 days of March 28, 2024. And
10,586 vested RSUs. |
(6) |
Mr. Yair Shamir is a director of CEL Catalyst Communications Limited and has the power to direct it to vote and dispose of the shares
and has shared voting and investment power over the shares. Mr. Yair Shamir disclaims any beneficial ownership of any shares owned by
CEL Catalyst Communications Limited other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
|
(7) |
Consists of 39,600 SatixFy Ordinary Shares underlying options to acquire SatixFy Ordinary Shares
exercisable within 60 days of March 28, 2024. |
(8) |
Consists of 21,903,349 SatixFy Ordinary Shares held directly. Mr. Yoav Leibovitch is one of SatixFy’s
founders. Mr. Yoav Leibovitch’s holdings include 18,000,000 Price Adjustment Shares and 1,403,981 SatixFy Ordinary Shares underlying
options to acquire SatixFy Ordinary Shares exercisable within 60 days of March 28, 2024 |
(9) |
Consists of 53,328 SatixFy Ordinary Shares underlying options to acquire SatixFy Ordinary Shares exercisable
within 60 days of March 28, 2024. And 54,688 vested RSUs |
(10) |
Consists of 64,944 SatixFy Ordinary Shares underlying options to acquire SatixFy Ordinary Shares exercisable
within 60 days of March 28, 2024.and 54,688 vested RSUs |
B. |
Related Party Transactions |
C. |
Interests of Experts and Counsel |
A. |
Financial Statements and Other Financial Information |
B. |
Significant Changes |
A. |
Offer and Listing Details |
B. |
Plan of Distribution |
C. |
Markets |
D. |
Selling Shareholders |
E. |
Dilution |
F. |
Expenses of the Issue |
A. |
Share Capital |
B. |
Memorandum and Articles of Association |
C. |
Material Contracts |
D. |
Exchange Controls |
E. |
Taxation |
• |
Amortization of the cost of purchased patent, rights to use a patent, and know-how, which were purchased in good faith and are used
for the development or advancement of the Industrial Enterprise, over an eight-year period, commencing on the year in which such rights
were first exercised; |
• |
Under limited conditions, an election to file consolidated tax returns with controlled Israeli Industrial Companies; |
• |
Expenses related to a public offering are deductible in equal amounts over three years commencing on the year of the offering.
|
• |
The research and development expenditures are approved by the relevant Israeli government ministry, determined by the field of research;
|
• |
The research and development must be for the promotion of the company; and |
• |
The research and development is carried out by or on behalf of the company seeking such tax deduction. |
• |
banks, insurance companies, and certain other financial institutions; |
• |
regulated investment companies and real estate investment trusts; |
• |
brokers, dealers or traders in securities that use a mark to market method of tax accounting; |
• |
tax-exempt organizations or governmental organizations; |
• |
U.S. expatriates and former citizens or long-term residents of the United States; |
• |
persons holding SatixFy Ordinary Shares and/or SatixFy Warrants, as the case may be, as part of a hedge, straddle, constructive sale,
or other risk reduction strategy or as part of a conversion transaction or other integrated investment; |
• |
persons subject to special tax accounting rules as a result of any item of gross income with respect to SatixFy Ordinary Shares and/or
SatixFy Warrants, as the case may be, being taken into account in an applicable financial statement; |
• |
persons that actually or constructively own 5% or more (by vote or value) of the outstanding SatixFy Ordinary Shares; |
• |
“controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate
earnings to avoid U.S. federal income tax; |
• |
S corporations, partnerships or other entities or arrangements treated as partnerships or other flow- through entities for U.S. federal
income tax purposes (and investors therein); |
• |
persons subject to the “base erosion and anti-abuse” tax; |
• |
U.S. Holders having a functional currency other than the U.S. dollar; |
• |
persons who hold or received SatixFy Ordinary Shares and/or SatixFy Warrants, as the case may be, pursuant to the exercise of any
employee share option or otherwise as compensation; and |
• |
tax-qualified retirement plans. |
• |
an individual who is a citizen or resident of the United States; |
• |
a corporation (or other entity taxable as a corporation) created or organized under the laws of the United States, any state thereof,
or the District of Columbia; |
• |
an estate, the income of which is subject to U.S. federal income tax regardless of its sources; or |
• |
a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons”
(within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a “United States
person” (within the meaning of Section 7701(a)(30) of the Code) for U.S. federal income tax purposes. |
• |
the SatixFy Ordinary Shares are readily tradable on an established securities market in the United States; |
• |
SatixFy is neither a PFIC (as discussed below under “— Passive Foreign Investment Company
Rules”) nor treated as such with respect to the U.S. Holder in any taxable year in which the dividend is paid or the preceding
taxable year; |
• |
the U.S. Holder satisfies certain holding period requirements; and |
• |
the U.S. Holder is not under an obligation to make related payments with respect to positions in substantially similar or related
property. |
• |
at least 75% of its gross income for such year is passive income; or |
• |
at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets) during such year is
attributable to assets that produce passive income or are held for the production of passive income. |
• |
Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange of property
producing such income and net foreign currency gains. For this purpose, cash is categorized as a passive asset and the company’s
unbooked intangibles associated with active business activity are taken into account as a non- passive asset. Goodwill is an active asset
under the PFIC rules to the extent attributable to activities that produce active income. For this purpose, SatixFy will be treated as
owning its proportionate share of the assets and earning its proportionate share of the income of any other entity treated as a corporation
for U.S. federal income tax purposes in which SatixFy owns, directly or indirectly, 25% or more (by value) of the stock. |
• |
Whether SatixFy or any of its subsidiaries is treated as a PFIC is determined on an annual basis. Based on the current and anticipated
composition of our and our subsidiaries’ income, assets and operations, including goodwill, which is based on the trading prices
of our Satixfy Ordinary Shares during 2023, we believe that we were not a PFIC for the taxable year of 2022. However, whether we or any
of our subsidiaries are a PFIC for any taxable year is a factual determination that depends on, among other things, the composition of
our and our subsidiaries’ income and assets. Changes in the composition of our and our subsidiaries’ income or assets may
cause us to be or become a PFIC for the current or subsequent taxable years. In addition, because the value of our goodwill may be determined
based on our market capitalization, the decline in our market capitalization (or a further such decline) could cause us to be treated
as a PFIC for 2022, the current taxable year or a future taxable year. Our PFIC status for our 2023 taxable year can be determined only
after the end of the year. Even if the value of our goodwill is respected for 2022, we may be a PFIC for the current taxable year or future
taxable years if our market capitalization does not increase significantly and we continue to hold substantial amounts of cash and financial
investments. Therefore, there is a risk that we may be a PFIC due to our declined market capitalization. The application of the PFIC rules
is subject to uncertainty in several respects, and SatixFy can make no assurances that the IRS will not take a contrary position or that
a court will not sustain such a challenge by the IRS. |
• |
the excess distribution or gain will be allocated ratably over the U.S. Holder’s holding period for the SatixFy Ordinary Shares
and/or SatixFy Warrants; |
• |
the amount allocated to the current taxable year, and any taxable years in the U.S. Holder’s holding period prior to the first
taxable year in which SatixFy is a PFIC, will be treated as ordinary income; and |
• |
the amount allocated to each other taxable year will be subject to the highest tax rate in effect for individuals or corporations,
as applicable, for each such year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting
tax attributable to each such year. |
• |
a nonresident alien individual, other than certain former citizens and residents of the United States; |
• |
a foreign corporation; or |
• |
a foreign estate or trust. |
• |
the gain or distribution is effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United
States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States
to which such gain is attributable); or |
• |
in the case of any gain, the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more
during the taxable year of the disposition and certain other requirements are met. |
F. |
Dividends and Paying Agents |
G. |
Statement by Experts |
H. |
Documents on Display |
I. |
Subsidiary Information |
A. |
Debt Securities |
B. |
Warrants and Rights |
C. |
Other Securities |
D. |
American Depositary Shares |
(a) |
Disclosure Controls and Procedures |
(b) |
Management’s Annual Report on Internal Control over Financial
Reporting |
(c) |
Attestation Report of Registered Public Accounting Firm
|
(d) |
Changes in Internal Control Over Financial Reporting
|
Year Ended December 31,
|
||||||||
Services Rendered |
2023 |
2022
|
||||||
(U.S. dollars in thousands)
|
||||||||
Audit fees (1) |
230 |
343 |
||||||
Audit-related fees (2) |
69 |
146 |
||||||
Tax fees (3) |
20 |
12 |
||||||
All Other Fees |
- |
- |
||||||
Total |
319 |
501 |
(1) |
Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements,
including services that generally only the independent accountant can reasonably provide. |
(2) |
Audit-related fees relate to work regarding preparation of our Registration Statement on Form F-1 and ongoing consultation.
|
(3) |
Tax fees relate to tax compliance, planning and advice. |
• |
did not implement and publish corporate governance guidelines; |
• |
do not have a lead independent or non-management director that presides over regularly scheduled meetings of the Board without the
participation of management; |
• |
have a compensation committee that complies with Israeli law and may not comply with all of the NYSE requirements applicable to U.S.
domestic public companies, including the requirements that the compensation committee must be composed entirely of directors determined
to be independent under NYSE compensation committee rules and conduct an independence assessment with respect to any compensation consultant,
legal counsel or other adviser that provides advice to the compensation committee; |
• |
adopt and approve material changes to equity incentive plans in accordance with the Israeli Companies Law, which does not impose
a requirement of shareholder approval for such actions, instead of the NYSE corporate governance rule, which requires shareholder approval
prior to an issuance of securities in connection with equity-based compensation of officers, directors, employees or consultants;
|
• |
follow the quorum requirements for shareholder meetings under the Israeli Companies Law instead of the NYSE corporate governance
requirements, which would require 33-1⁄3% of the |
• |
total outstanding voting power of our shares present at meetings, as further described in “Description of SatixFy Ordinary
Shares — Voting Rights — Quorum Requirements;” and |
• |
follow Israeli corporate governance practice in respect of private placements instead of the NYSE corporate governance requirements
to obtain shareholder approval for certain dilutive events, such as issuances that will result in a change of control, certain transactions
other than a public offering involving issuances of a 20% or greater equity interest in us and certain acquisitions of the stock or assets
of another company. |
1.1 |
2.1 |
2.2 |
2.3 |
2.4* |
4.1 |
4.2 |
4.3 |
4.4 |
4.6 |
4.7 |
4.8 |
4.9 |
4.10 |
4.11 |
4.12 |
4.13 |
4.14 |
4.15 |
4.16 |
4.17 |
4.18 |
4.19 |
4.20 |
4.21 |
4.22 |
4.23 |
4.24* |
8.1* |
12.1* |
12.2* |
13.1** |
13.1** |
15.1* |
97.1* |
101 |
The following financial statements from the Company’s 20-F for the fiscal year ended December 31, 2023, formatted in Inline
XBRL: (i) Consolidated Statements of Financial Position, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements
of Shareholders’ Deficit, (iv) Consolidated Statements of Cash Flows and (v) Notes to the Consolidated Financial Statements.
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SATIXFY COMMUNICATIONS LTD | ||
| ||
By: |
![]() | |
Name: Nir Barkan | ||
Title: Acting Chief Executive Officer | ||
By: |
![]() |
|
Name: Oren Harari | ||
Title: Interim Chief Financial Officer | ||
Date: March 29, 2024 |
Report of Independent registered public accounting firm (Ziv Haft; Tel-Aviv, Israel; PCAOB ID#1185)
|
F-2
|
F-3 - F-4
|
|
F-5
|
|
F-6 - F-8
|
|
F-9 - F-11
|
|
F-12 - F-78
|
March 28, 2024
|
||||||
Date of approval of the financial statements
|
Nir Barkan
Acting CEO
|
Oren Harari
Interim CFO
|
Yoav Leibovitch
Chairman of Board
|
As of December 31,
|
|||||||||||
2023
|
2022
|
||||||||||
Note
|
In USD thousands
|
||||||||||
LIABILITIES AND SHAREHOLDERS’ DEFICIT
|
|||||||||||
CURRENT LIABILITIES:
|
|||||||||||
Trade payables
|
1,378
|
1,459
|
|||||||||
Contract Liabilities
|
9
|
1,720
|
622
|
||||||||
ESA advance payments
|
19 (a)
|
3,842
|
5,800
|
||||||||
Prepayment from Customer
|
3,858
|
(*) | 3,301 |
|
|||||||
Advanced payments from MDA against future orders
|
3
|
28,138
|
(*) | 8,875 |
|
||||||
Lease liabilities
|
6
|
639
|
1,021
|
||||||||
Other accounts payable and accrued expenses
|
10
|
9,704
|
7,843
|
||||||||
Related Parties
|
14
|
740
|
408
|
||||||||
Total current liabilities
|
50,019
|
29,329
|
|||||||||
NON-CURRENT LIABILITIES:
|
|||||||||||
Long term loans from financial institutions, net
|
12
|
59,792
|
54,926
|
||||||||
Lease liabilities
|
6
|
2,067
|
2,280
|
||||||||
Derivatives Instruments Liabilities
|
15
|
114
|
20,305
|
||||||||
Other long-term liabilities
|
16
|
1,496
|
1,107
|
||||||||
Total non-current liabilities
|
63,469
|
78,618
|
|||||||||
SHAREHOLDERS’ DEFICIT:
|
18
|
||||||||||
Share Capital
|
-
|
-
|
|||||||||
Share Premium
|
451,093
|
446,488
|
|||||||||
Capital reserves
|
1,444
|
3,498
|
|||||||||
Accumulated deficit
|
(511,323
|
)
|
(481,608
|
)
|
|||||||
Total shareholders’ deficit
|
(58,786
|
)
|
(31,622
|
)
|
|||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT
|
54,702
|
76,325
|
For the year ended December 31
|
|||||||||||||||
Note
|
2023
|
2022
|
2021
|
||||||||||||
Revenues:
|
20
|
||||||||||||||
Development services and preproduction
|
8,249
|
10,081
|
19,237
|
||||||||||||
Sale of products
|
2,481
|
545
|
2,483
|
||||||||||||
Total revenues
|
10,730
|
10,626
|
21,720
|
||||||||||||
Cost of sales and services:
|
21
|
||||||||||||||
Development services and preproduction
|
4,930
|
4,166
|
7,326
|
||||||||||||
Sale of products
|
1,008
|
332
|
1,517
|
||||||||||||
Total cost of sales and services
|
5,938
|
4,498
|
8,843
|
||||||||||||
Gross profit
|
4,792
|
6,128
|
12,877
|
||||||||||||
Research and development expenses, Net
|
22
|
29,126
|
16,842
|
17,944
|
|||||||||||
Selling and marketing expenses
|
23
|
2,866
|
2,335
|
1,752
|
|||||||||||
General and administrative expenses
|
24
|
14,561
|
9,249
|
3,735
|
|||||||||||
Loss from operations
|
(41,761
|
)
|
(22,298
|
)
|
(10,554
|
)
|
|||||||||
Finance Income
|
83
|
17
|
-
|
||||||||||||
Finance Expenses
|
(12,129
|
)
|
(9,919
|
)
|
(4,399
|
)
|
|||||||||
Derivatives revaluation
|
15
|
(17,217
|
)
|
(37,377
|
)
|
(199
|
)
|
||||||||
Other Income
|
3
|
41,657
|
5,474
|
-
|
|||||||||||
Listing Expenses
|
25
|
-
|
(333,326
|
)
|
-
|
||||||||||
Company's share in the loss of a company accounted by equity method, net
|
7
|
(226
|
)
|
(360
|
)
|
(1,898
|
)
|
||||||||
Loss before income taxes
|
(29,593
|
)
|
(397,789
|
)
|
(17,050
|
)
|
|||||||||
Tax expenses
|
26
|
(122
|
) |
-
|
-
|
||||||||||
Loss for the period
|
(29,715
|
)
|
(397,789
|
)
|
(17,050
|
)
|
|||||||||
Other comprehensive income (loss) net of tax:
|
|||||||||||||||
Items that will or may be reclassified to profit or loss:
|
|||||||||||||||
Exchange gain (loss) arising on translation of foreign operations
|
(609
|
)
|
3,272
|
1,131
|
|||||||||||
Total comprehensive loss for the period
|
(30,324
|
)
|
(394,517
|
)
|
(15,919
|
)
|
|||||||||
Basic and diluted loss per share (in dollars)
|
27
|
(0.37
|
)
|
(13.25
|
)
|
(0.91
|
)
|
||||||||
Basic and diluted weighted average common shares outstanding (quantity)
|
80,975
|
30,031
|
18,732
|
Ordinary shares
|
Preferred Shares A
|
Preferred Shares B
|
Preferred Shares C
|
Share capital
|
Share premium
|
Accumulated deficit
|
Capital reserves
|
Total
|
||||||||||||||||||||||||||||
Number of shares
|
In USD thousand
|
|||||||||||||||||||||||||||||||||||
Balance as of January 1, 2023
|
80,672,674
|
-
|
-
|
-
|
-
|
446,488
|
(481,608
|
)
|
3,498
|
(31,622
|
)
|
|||||||||||||||||||||||||
Shares issued to employees
|
940,953
|
-
|
-
|
-
|
-
|
27
|
-
|
-
|
27
|
|||||||||||||||||||||||||||
Shares issued to Financial Institutions
|
1,500,566
|
-
|
-
|
-
|
-
|
1,628
|
-
|
-
|
1,628
|
|||||||||||||||||||||||||||
Share based payments
|
-
|
-
|
-
|
-
|
-
|
2,950
|
-
|
2,950
|
||||||||||||||||||||||||||||
Comprehensive Loss for the year
|
-
|
-
|
-
|
-
|
-
|
(29,715
|
)
|
(609
|
)
|
(30,324
|
)
|
|||||||||||||||||||||||||
Currency translation reserve realization due the sell of SSS |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,445
|
)
|
(1,445
|
)
|
|||||||||||||||||||||||||
Balance as of December 31, 2023
|
83,114,193
|
-
|
-
|
-
|
-
|
451,093
|
(511,323
|
)
|
1,444
|
(58,786
|
)
|
Ordinary shares
|
Preferred Shares A
|
Preferred Shares B
|
Preferred Shares C
|
Share capital
|
Share premium
|
Accumulated deficit
|
Capital reserves
|
Total
|
||||||||||||||||||||||||||||
Number of shares
|
In USD thousand
|
|||||||||||||||||||||||||||||||||||
Balance as of January 1, 2022
|
18,783,168
|
7,638,647
|
4,999,651
|
895,710
|
4
|
46,203
|
(83,819
|
)
|
226
|
(37,386
|
)
|
|||||||||||||||||||||||||
Exercise of employee's options
|
236,446
|
-
|
-
|
-
|
|
101
|
-
|
-
|
101
|
|||||||||||||||||||||||||||
Shares issued to Financial Institutions
|
846,432
|
-
|
-
|
-
|
-
|
1,978
|
-
|
-
|
1,978
|
|||||||||||||||||||||||||||
Warrant exercised
|
-
|
-
|
57,660
|
860,802
|
-
|
5,399
|
-
|
-
|
5,399
|
|||||||||||||||||||||||||||
Share based payments
|
-
|
-
|
-
|
-
|
|
570
|
-
|
-
|
570
|
|||||||||||||||||||||||||||
Issuance of shares following SPAC transaction- (see note 1)
|
56,647,836
|
(7,638,647
|
)
|
(5,057,311
|
)
|
(1,756,512
|
)
|
(4
|
)
|
339,858
|
-
|
-
|
339,854
|
|||||||||||||||||||||||
SPAC Exercise of warrants
|
2,553,692
|
-
|
-
|
-
|
-
|
2,381
|
-
|
-
|
2,381
|
|||||||||||||||||||||||||||
Issuing shares as part of FPA
|
1,605,100
|
-
|
-
|
-
|
-
|
49,998
|
-
|
-
|
49,998
|
|||||||||||||||||||||||||||
Comprehensive Loss for the year
|
-
|
-
|
-
|
-
|
-
|
-
|
(397,789
|
)
|
3,272
|
(394,517
|
)
|
|||||||||||||||||||||||||
Balance as of December 31, 2022
|
80,672,674
|
-
|
-
|
-
|
-
|
446,488
|
(481,608
|
)
|
3,498
|
(31,622
|
)
|
Ordinary shares
|
Preferred Shares A
|
Preferred Shares B
|
Preferred Shares C
|
Share capital
|
Share premium
|
Accumulated deficit
|
Capital reserves
|
Total
|
||||||||||||||||||||||||||||
Number of shares
|
In USD thousand
|
|||||||||||||||||||||||||||||||||||
Balance as of January 1, 2021
|
18,722,010
|
7,638,647
|
4,999,651
|
895,710
|
4
|
45,990
|
(66,769
|
)
|
(905
|
)
|
(21,680
|
)
|
||||||||||||||||||||||||
Exercise of options
|
61,158
|
-
|
-
|
-
|
(
|
)
|
64
|
-
|
-
|
64
|
||||||||||||||||||||||||||
Share based payments
|
-
|
-
|
-
|
-
|
(
|
)
|
149
|
|
|
149
|
||||||||||||||||||||||||||
Comprehensive Loss for the year
|
-
|
-
|
-
|
-
|
-
|
-
|
(17,050
|
)
|
1,131
|
(15,919
|
)
|
|||||||||||||||||||||||||
Balance as of December 31, 2021
|
18,783,168
|
7,638,647
|
4,999,651
|
895,710
|
4
|
46,203
|
(83,819
|
)
|
226
|
(37,386
|
)
|
For the year ended December 31
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Loss for the year
|
(29,715
|
)
|
(397,789
|
)
|
(17,050
|
)
|
||||||
Adjustments to reconcile net profit to net cash provided by operating activities:
|
||||||||||||
Depreciation and amortization
|
1,245
|
1,162
|
1,421
|
|||||||||
Company's share in the loss of a company accounted by equity method, net
|
226
|
360
|
1,898
|
|||||||||
Finance expenses on loans
|
6,613
|
5,211
|
917
|
|||||||||
Change in the fair value of derivatives
|
17,227
|
37,374
|
200
|
|||||||||
Share based payments
|
2,950
|
570
|
149
|
|||||||||
Adjustment to Loss due to SPAC transaction
|
-
|
332,272
|
-
|
|||||||||
Decrease (Increase) in trade accounts receivable
|
(885
|
)
|
(587
|
)
|
(305
|
)
|
||||||
Decrease (Increase) in contract assets
|
1,220
|
537
|
(4,119
|
)
|
||||||||
Increase in inventory
|
(644
|
)
|
(146
|
)
|
(10
|
)
|
||||||
Decrease (Increase) in other current assets
|
3,508
|
(7,007
|
)
|
3,256
|
||||||||
Increase (Decrease) in trade payables
|
(75
|
)
|
(6,236
|
)
|
1,461
|
|||||||
Increase (Decrease) in ESA prepayments
|
(1,268
|
)
|
(7,609
|
)
|
1,882
|
|||||||
Decrease in deferred revenues
|
-
|
-
|
(612
|
)
|
||||||||
Increase (Decrease) in other accounts payable and accrued expenses
|
(2,601
|
) |
(1,571
|
)
|
3,282
|
|||||||
Increase in prepayments from customers
|
682
|
2,936
|
1,504
|
|||||||||
Increase Prepayments from MDA (See note 3)
|
18,139
|
8,875
|
-
|
|||||||||
MDA Agreement (See note 3)
|
(41,657
|
)
|
-
|
-
|
||||||||
Increase in other long-term liabilities
|
300
|
-
|
-
|
|||||||||
Increase in liability for royalties payable
|
100
|
168
|
260
|
|||||||||
Net cash used in operating activities
|
(24,635
|
)
|
(31,480
|
)
|
(5,866
|
)
|
||||||
Cash flows from investing activities
|
||||||||||||
Decrease (Increase) in long-term bank deposit
|
(7
|
)
|
(11
|
)
|
201
|
|||||||
Proceeds from selling a subsidiary (See Appendix C)
|
17,583
|
-
|
-
|
|||||||||
Purchase of property, plant and equipment
|
(235
|
)
|
(571
|
)
|
(211
|
)
|
||||||
Net cash provided (used in) investing activities
|
17,341
|
(582
|
)
|
(10
|
)
|
|||||||
Cash flows from financing activities
|
||||||||||||
Receipt of long-term loans from a financial institution
|
-
|
52,837
|
7,300
|
|||||||||
Repayment of loan to shareholder
|
-
|
(5,000
|
)
|
-
|
||||||||
Repayment of loans from banks
|
-
|
(13,818
|
)
|
(2,930
|
)
|
|||||||
Repayment of royalty liability
|
(11
|
) |
(429
|
)
|
(488
|
)
|
||||||
Payments of lease liabilities
|
(927
|
)
|
(1,029
|
)
|
(1,191
|
)
|
||||||
Issuance of shares- SPAC transactions
|
-
|
1,362
|
-
|
|||||||||
Option exercises to shares by employees
|
26
|
100
|
64
|
|||||||||
Exercise of Warrants, net
|
-
|
6,500
|
-
|
|||||||||
Issuance of shares to FPA (See note 17)
|
10,026
|
-
|
-
|
|||||||||
Net cash provided by financing activities
|
9,114
|
40,523
|
2,755
|
|||||||||
Increase (decrease) in cash and cash equivalents
|
1,820
|
8,461
|
(3,121
|
)
|
||||||||
Cash and cash equivalents balance at the beginning of the year
|
11,934
|
3,854
|
6,983
|
|||||||||
Effect of changes in for foreign exchange rates on cash and cash equivalents
|
225
|
(381
|
)
|
(8
|
)
|
|||||||
Cash and cash equivalents balance at the end of the year
|
13,979
|
11,934
|
3,854
|
For the year ended December 31
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Appendix A – Cash paid and received during the year for:
|
||||||||||||
Interest paid
|
1,241
|
921
|
1,625
|
|||||||||
Appendix B – Non Cash transactions during the year for:
|
||||||||||||
Purchase of Fixed Assets in credit
|
-
|
319
|
-
|
|||||||||
Issuance of shares against liability
|
-
|
49,998
|
-
|
|||||||||
Issuance of shares against loan
|
1,628
|
1,978
|
-
|
|||||||||
Issuance of shares against warrants
|
-
|
1,280
|
-
|
For the year ended
December 31
|
||||
2023
|
||||
Appendix C – Proceeds from selling a subsidiary
|
||||
Cash that was sold
|
417
|
|||
Prepaid expenses and other
|
218
|
|||
Short term Deposits
|
85
|
|||
Other accounts receivables
|
932
|
|||
Property, plant and equipment, net
|
150
|
|||
Trade accounts payable
|
(175
|
)
|
||
Contract liabilities
|
(96
|
)
|
||
Other accounts payable
|
(585
|
)
|
||
ESA Prepayments
|
(994
|
)
|
||
Related party
|
(164
|
)
|
||
Capital Gain
|
41,657
|
|||
Capital reserve
|
(1,445 | ) | ||
Net assets and liabilities
|
40,000
|
|||
Less assets received
|
||||
Promissory Notes
|
20,000
|
|||
Other long-term receivables
|
2,000
|
|||
Cash received
|
18,000
|
|||
Cash sold
|
(417
|
)
|
||
Net Cash inflows
|
17,583
|
The accompanying notes are an integral part of the financial statements
a. |
Satixfy Communications LTD (hereinafter: the "Company") was originally incorporated in Hong Kong as Satixfy Limited in 2012 and in 2020 was reorganized and re-incorporated in Israel as a private limited company, in accordance with the provisions of the Israeli Companies Law with the approval from the Israeli Tax Authorities for tax exemption in accordance with the provisions of section 104B (f) of the Income Tax Ordinance.
|
b. |
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
|
c. |
Business Combination Agreement SPAC Transaction ("Business Combination Agreement" OR "Transactions"):
|
d. |
The Company and its subsidiaries are engaged in the development and marketing of integrated circuit products for specific applications, antennas and terminals used for satellite communications. The Company has developed a new generation of integrated silicon chips for modems and antennas based on its own proprietary technology and provides end-to-end solutions for the satellite communications industry, including terminals, payload subsystems and hubs. The Company develops its advanced chips (Application Specific Integrated Circuit chips (ASICs) and Radio Frequency Integrated Circuit chips (RFICs)) based on technology designed to meet a variety of applications and services, such as broadband aviation, IOT, mobility and maritime, and operating on GEO, LEO and MEO satellites. The Company’s technology includes electronically steered antenna arrays, forming and design of digital beams, beam hopping, on-board processing payload chips and software-defined radio (SDR) modem chips. The affiliated company "Jet Talk" is engaged in the development and marketing of a unique antenna for IFC passenger aircraft and computers that receive broadband video transmissions from satellites.
|
e. |
The Company operates primarily through five wholly owned subsidiaries: Satixfy Israel LTD, Satixfy UK Limited, Satixfy Space Systems UK (hereinafter: “SSS) (which was sold in October 2023 to MDA- See note 3), Satixfy Bulgaria Eood and SatixFy US LLC (collectively together with Company, the "Group"), all of which have been consolidated in these consolidated financial statements.
|
Name
|
Holding percentage as of December 31,
|
Held By
|
Country of incorporation
|
||||||||
2023
|
2022
|
||||||||||
Satixfy Israel LTD.
|
100
|
%
|
100
|
%
|
Satixfy Communications LTD.
|
Israel
|
|||||
Satixfy UK
|
100
|
%
|
100
|
%
|
Satixfy Communications LTD.
|
England and Wales
|
|||||
Satixfy Space Systems UK (See Note 3)
|
0
|
%
|
100
|
%
|
Satixfy Communications LTD.
|
England and Wales
|
|||||
Satixfy Bulgaria
|
100
|
%
|
100
|
%
|
Satixfy UK
|
Bulgaria
|
|||||
Satixfy US LLC
|
100
|
%
|
100
|
%
|
Satixfy Communications LTD.
|
USA
|
|||||
Endurance Acquisition Corporation
|
100
|
%
|
100
|
%
|
Satixfy Communications LTD.
|
Cayman Islands
|
F - 13
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
Name
|
Holding percentage
as of December 31, |
Held By |
Country of incorporation
|
||||||||
2023
|
2022
|
||||||||||
Jet talk Limited (“Jet-Talk”)
|
51
|
%
|
51
|
%
|
Satixfy UK
|
UK
|
f. |
Russia- Ukraine war:
|
g. |
Israel - Hamas War:
|
F - 14
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 1 - GENERAL (CONT.):
g. |
Israel - Hamas War (Cont.):
|
|
F - 15
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 1 - GENERAL (CONT.):
g. |
Israel -Hamas War (Cont.):
|
|
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
A. |
Basis of preparation:
|
B. |
Basis of consolidation:
|
F - 17
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
B. |
Basis of consolidation (cont.):
|
C. |
Use of critical estimates and assumptions in the preparation of the financial statements:
|
F - 19
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
C. |
Use of estimates and assumptions in the preparation of the financial statements (Cont.):
|
D. |
Foreign currency:
|
• |
Monetary assets and liabilities – at the rate of exchange applicable at the consolidated statements of financial position date.
|
• |
Exchange gains and losses from the aforementioned conversion are recognized in the statement of comprehensive loss.
|
• |
Expense items – at exchange rates applicable as of the date of recognition of those items.
|
|
• |
Non-monetary items are converted at the rate of exchange used to convert the related consolidated statements of financial position items (i.e., converted at the time of the transaction).
|
F - 20
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
D. |
Foreign currency (Cont.):
|
E. |
Cash and cash equivalents:
|
F. |
Linkage:
|
G. |
Provisions:
|
F - 21
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
G. |
Provisions (Cont.):
|
H. |
Research and development costs:
|
• |
the product is technically and commercially feasible;
|
• |
the Company intends to complete the product so that it will be available for use or sale;
|
• |
the Company has the ability to use the product or sell it;
|
• |
the Company has the technical, financial and other resources to complete the development and to use or sell the product;
|
• |
the Company can demonstrate the probability that the product will generate future economic benefits; and.
|
• |
the Company is able to measure the expenditure attributable to the product during the development.
|
I. |
Leases:
|
• |
Applied a single discount rate to a portfolio of leases with reasonably similar characteristics.
|
• |
Applied the exemption not to recognize right-of-use assets and liabilities for leases with less than 12 months of lease term remaining as of the date of initial application and do not contain a purchase option.
|
• |
Applied the practical expedient provided by the standard to recognize right-of-use assets equal to the lease liability upon initial application.
|
F - 23
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
I. |
Leases (Cont.):
|
J. |
Share-based payment:
|
F - 24
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
J. |
Share-based payment (Cont.):
|
K. |
Transactions with related parties:
|
L. |
Loss per share:
|
M. |
IIA grants:
|
N. |
Credit costs:
|
O. |
Capital instrument:
|
P. |
Warrants:
|
Q. |
Fair value measurement:
|
Level 1
|
-
|
Quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
Level 2
|
-
|
Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly.
|
Level 3
|
-
|
Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
|
R. |
Financial instruments:
|
F - 29
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
R. |
Financial instruments (Cont.):
|
• |
Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive loss.
|
• |
Amortized cost: other financial liabilities, including bank borrowings, loans from bank, trade payables, loan from major shareholder, leases and financial liability from government grants, are initially recognized at fair value less any transaction costs directly attributable to the issue of the instrument. Such interest-bearing liabilities are subsequently measured at amortized cost using the effective interest method, which ensures that any interest expense over the period is at a constant interest rate on the balance of the liability carried in the statement of financial position. Interest expense in this context includes initial transaction costs, as well as any interest or coupon payable while the liability is outstanding.
|
F - 30
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
R. |
Financial instruments (Cont.):
|
● |
Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive income.
|
● |
Financial Liabilities - the Company derecognizes financial liability when its contractual obligations are discharged or cancelled or expire.
|
1. |
Inability to locate the debtor.
|
2. |
Discharge of the debt in a bankruptcy.
|
3. |
It is determined that the efforts to collect the debt are no longer cost effective given the size of receivable.
|
S. |
Issue of a unit of financial instruments:
|
T. |
Impairment of non-financial assets:
|
U. |
Assets and liabilities arising from engagements with customers:
|
• |
Customers -
|
The Company presents an unconditional right to receive consideration as debtors in respect of contracts (customers). The right to compensation is not conditional if only a lapse of time is required until the due date, even if it may be subject to repayment in the future. Upon first recognition of customers, any difference between the measurement of customers in accordance with IFRS 9 and the corresponding amount of recognized revenue will be presented as an expense. The Company treats debtors in respect of contracts as financial assets.
• |
Assets in respect of contracts –
|
The Company presents a right to receive consideration for goods or services transferred to the customer as an asset in respect of a contract, when this right is conditional on a factor other than the passage of time. The Company handles the impairment of an asset in respect of a contract on the same basis as a financial asset at a reduced cost.
• |
Liabilities in respect of contracts –
|
The Company presents an obligation to transfer goods or services to the customer, for which the company has received consideration from the customer (or unconditional consideration that has matured), as an obligation in respect of a contract (advances from customers).
V. |
Inventories:
|
W. |
Property, plant and equipment:
|
%
|
||||
Leasehold Improvement
|
25-33
|
(*) | ||
Machinery and Equipment
|
7-14
|
|||
Computers
|
33.3
|
|||
Furniture
|
15
|
X. |
Employee benefits:
|
1. |
Short-term employee benefits: Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made.
|
2. |
Post-employment benefits: The plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. In Israel, the Group funds its employee’s contribution plans pursuant to Section 14 to the Severance Pay Law since 2004 under which the Group pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods. There are no post-employment benefits in the UK.
|
Y. |
Revenue recognition:
|
1. |
Identify the contracts with a customer.
|
2. |
Identify the performance obligations in the contract.
|
3. |
Determine the transaction price.
|
4. |
Allocate the transaction price to the performance obligations in the contract.
|
5. |
Recognize revenue when the entity satisfies a performance obligation.
|
F - 34
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
Y. |
Revenue recognition (cont.):
|
F - 35
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
Y. |
Revenue recognition (Cont.):
|
• |
SatixFy’s existing shareholders have the greatest voting interest in the combined entity.
|
• |
SatixFy’s directors represent the majority of the board of directors of the combined company following the consummation of the Business Combination.
|
• |
SatixFy’s senior management were the senior management of the combined company following the consummation of the Business Combination.
|
• |
SatixFy is the larger entity based on historical operating activity and its employee base.
|
• |
Warrants and Price Adjustments Shares ("PAS") in the scope of IFRS 2 will be classified as equity, as they are considered equity-settled share-based payment.
|
• |
Warrants and price adjustment shares in the scope of IAS 32 will be classified as financial liabilities, as they fail the fixed-for-fixed requirement.
|
• |
IFRS 16 Leases (Amendment – Liability in a Sale and Leaseback)
|
• |
IAS 1 Presentation of Financial Statements (Amendment – Classification of Liabilities as Current or Non-current)
|
F - 38
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):
• |
Non-current Liabilities with Covenants (Amendments to IAS 1 Presentation of Financial Statements); and
|
• |
Supplier Finance Arrangements (Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures).
|
• |
Lack of Exchangeability (Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates).
|
F - 39
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
F - 40
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
|
December 31, 2023
|
December 31, 2022
|
||||||
Related parties (See Note 14)
|
-
|
$ |
1,679
|
|||||
Other trade receivables
|
4,091
|
3,356
|
||||||
|
$ |
4,091
|
$ |
5,035
|
December 31, 2023
|
December 31, 2022
|
|||||||
Balance at the beginning of the year
|
5,035
|
6,015
|
||||||
Revenue recognition in the period, net
|
643
|
(426
|
)
|
|||||
Provision
|
(1,876
|
)
|
-
|
|||||
Currency translation adjustments
|
289
|
(554
|
)
|
|||||
Balance at the End of the year
|
$
|
4,091
|
$
|
5,035
|
|
December 31, 2023
|
December 31, 2022
|
||||||
Raw materials
|
$ |
1,397
|
$ |
817
|
||||
Finished goods inventory
|
78
|
14
|
||||||
|
$ |
1,475
|
$ |
831
|
b. |
The following is a list of the carried values of the lease assets recognized and the transactions during the period:
|
Buildings
|
Cars
|
Total
|
||||||||||
Cost
|
||||||||||||
January 1, 2023
|
4,918
|
155
|
5,073
|
|||||||||
Additions
|
662
|
103
|
765
|
|||||||||
Disposals- Sale of SSS
|
(1,741
|
)
|
(74
|
)
|
(1,815
|
)
|
||||||
December 31, 2023
|
3,839
|
184
|
4,023
|
|||||||||
Accumulated Depreciation
|
||||||||||||
January 1, 2023
|
(2,256
|
)
|
(23
|
)
|
(2,279
|
)
|
||||||
Additions
|
(916
|
)
|
(83
|
)
|
(999
|
)
|
||||||
Disposals- Sale of SSS
|
1,454
|
36
|
1,490
|
|||||||||
December 31, 2023
|
(1,718
|
)
|
(70
|
)
|
(1,788
|
)
|
||||||
Net Book value December 31, 2023
|
2,121
|
114
|
2,235
|
Buildings
|
Cars
|
Total
|
||||||||||
Cost
|
||||||||||||
January 1, 2022
|
5,294
|
82
|
5,376
|
|||||||||
Additions
|
434
|
156
|
590
|
|||||||||
Disposals
|
(810
|
)
|
(83
|
)
|
(893
|
)
|
||||||
December 31, 2022
|
4,918
|
155
|
5,073
|
|||||||||
Accumulated Depreciation
|
||||||||||||
January 1, 2022
|
(2,155
|
)
|
(74
|
)
|
(2,229
|
)
|
||||||
Additions
|
(911
|
)
|
(32
|
)
|
(943
|
)
|
||||||
Disposals
|
810
|
83
|
893
|
|||||||||
December 31, 2022
|
(2,256
|
)
|
(23
|
)
|
(2,279
|
)
|
||||||
Net Book value December 31, 2022
|
2,662
|
132
|
2,794
|
c. |
Details regarding lease transactions:
|
For the year ended
|
||||||||
December 31, 2023
|
December 31, 2022
|
|||||||
Interest expenses in respect of lease liabilities
|
337
|
393
|
||||||
Lease principal payments during the year
|
927
|
1,029
|
F - 43
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
|
December 31, 2023
|
December 31, 2022
|
December 31, 2021
|
|||||||||
Net loss Company share
|
442
|
705
|
3,722
|
|||||||||
Company's share in the loss of a company accounted by equity method, net
|
226
|
360
|
1,898
|
Computers
|
Leasehold improvements
|
Furniture
|
Machinery and Equipment
|
Total
|
||||||||||||||||
Cost
|
||||||||||||||||||||
January 1, 2023
|
1,092
|
600
|
347
|
1,043
|
3,082
|
|||||||||||||||
Additions
|
113
|
52
|
5
|
65
|
235
|
|||||||||||||||
Disposal -SSS sale
|
(13
|
)
|
(119
|
)
|
-
|
(53
|
)
|
(185
|
)
|
|||||||||||
December 31, 2023
|
1,192
|
533
|
352
|
1,055
|
3,132
|
|||||||||||||||
Accumulated Depreciation
|
||||||||||||||||||||
January 1, 2023
|
(832
|
)
|
(262
|
)
|
(162
|
)
|
(183
|
)
|
(1,439
|
)
|
||||||||||
Additions
|
(156
|
)
|
(62
|
)
|
(29
|
)
|
(61
|
)
|
(308
|
)
|
||||||||||
Disposal -SSS sale
|
1
|
34
|
-
|
-
|
35
|
|||||||||||||||
December 31, 2023
|
(987
|
)
|
(290
|
)
|
(191
|
)
|
(244
|
)
|
(1,712
|
)
|
||||||||||
Net Book value December 31,2023
|
205
|
243
|
161
|
811
|
1,420
|
Computers
|
Leasehold improvements
|
Furniture
|
Machinery and Equipment
|
Total
|
||||||||||||||||
Cost
|
||||||||||||||||||||
January 1, 2022
|
956
|
477
|
345
|
414
|
2,192
|
|||||||||||||||
Additions
|
136
|
123
|
2
|
629
|
890
|
|||||||||||||||
December 31, 2022
|
1,092
|
600
|
347
|
1,043
|
3,082
|
|||||||||||||||
Accumulated Depreciation
|
||||||||||||||||||||
January 1, 2022
|
(714
|
)
|
(212
|
)
|
(138
|
)
|
(156
|
)
|
(1,220
|
)
|
||||||||||
Additions
|
(118
|
)
|
(50
|
)
|
(24
|
)
|
(27
|
)
|
(219
|
)
|
||||||||||
December 31, 2022
|
(832
|
)
|
(262
|
)
|
(162
|
)
|
(183
|
)
|
(1,439
|
)
|
||||||||||
Net Book value December 31,2022
|
260
|
338
|
185
|
860
|
1,643
|
F - 46
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
December 31, 2023
|
December 31, 2022
|
|||||||
Balance at the beginning of the year
|
622
|
475
|
||||||
Expenses recognition in the period, net
|
819
|
540
|
||||||
Currency translation adjustments
|
279
|
(393
|
)
|
|||||
Balance at the end of the year
|
$
|
1,720
|
$
|
622
|
|
December 31, 2023
|
December 31, 2022
|
||||||
Liabilities in respect of employees, wages and institutions in respect of wages
|
2,584
|
3,023
|
||||||
Accrued expenses
|
6,849
|
4,607
|
||||||
Liabilities to government institutions due to grants received
|
136
|
161
|
||||||
Tax accrual
|
122
|
-
|
||||||
Government departments and agencies
|
13
|
52
|
||||||
9,704
|
7,843
|
F - 47
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
a. |
In July 2016, the Israeli subsidiary entered into an agreement for a bank loan (hereinafter - the “First Loan") in the amount of $2,000 for a period of 36 months, at an annual interest rate of LIBOR + 6.9%. In addition, the Company issued warrant for a period of 6 years.
The warrant was exercised in July 2022 on a cashless basis to 57,659 shares.
The loan was fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from, Francisco Partners, See also Note 12(e).
|
b. |
In May 2019 and in March 2020, the Israeli subsidiary took out a loan including two portions from a bank in the amounts of $5 million and $3 million, respectively, for a period of 36 months (hereinafter: the “Second Loan"). The Company issued warrants for a period of 10 years.
Following the closing of the SPAC transaction on October 27, 2022 the Bank decided to receive the Alternative Payment instead of exercising the warrants and following that decision, the $800 Alternative Payment was paid to the Bank in February 2023.
The loan was repaid in full in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e). As part of the SPAC merger (see Note 1) the bank has exercised the warrants into cash. |
c.
|
In April 2020 and in September 2020 , following the COVID-19 pandemic, the Israeli subsidiary took out a five-year state-guaranteed bank loans on preferential terms bearing a yearly interest of premium plus 1.5. The loans were fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e).
|
d. |
In April 2021 and in August 2021 the Company signed a $5 million and $2.3 million loan agreement, respectively, with a financial institution named Liquidity Capital II L.P. (“Liquidity”), with a repayment period of thirty (30) months.
For that purpose, the Company granted to Liquidity a warrant for a period of eight (8) years,
Following the closing of the SPAC transaction on October 27, 2022 the warrants were exercised on a cashless basis into 6,520 ordinary shares.
The loan was fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e).
|
e. |
On February 1, 2022, the Company signed a $55 million loan agreement ("the 2022 Credit Agreement" with affiliates of a financial institution named Francisco Partners L.P. ("FP"), with a repayment period of between 2.5 to 4 years depending on the Company completing a qualified public offering within 12 months of closing. The loan beard a yearly interest of 9.5% on the outstanding balance. In the event the Company will not complete a qualified public offering during the first year, then the interest rate shall increase by 100 basis points per year beginning in year 2 up to a maximum rate of 11.5% total. As long as the Company was private, there was an ability to Pay In Kind (“PIK”) 100% of interest in year 1, 75% of interest in year 2, and 50% of interest thereafter. Once the Company completes a qualified public offering, then 100% of interest is paid in cash thereafter. Until October 27, 2022 the PIK interest of $3,988 was added to the loan balance.
|
|
For the year ended
December 31
|
|||||||
|
2023
|
2022
|
||||||
Long term loans from financial institutions
|
59,792
|
54,926
|
F - 50
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
On April 8, 2022 Mr. Yoel Gat, the Company’s former CEO, Chairman and founder passed away due to fatal illness and his entire holdings were inherited by Ms. Simona Gat.
On April 30, 2023, SatixFy Communications LTD. and Ilan Gat LTD. entered into a Separation Agreement pursuant to which Ms. Gat resigned from all positions at the Company and its subsidiaries, including serving as the President of the Company. Effective May 1, 2023, she instead began serving as an observer on the board of directors of the Company. The Company agreed to pay Ms. Gat compensation consisting of (i) five monthly payments in the gross sum of $55,000 plus VAT from May through September 2023; (ii) one monthly payment of $110,000 plus VAT in October 2023, totaling in the aggregate, $385,000 plus VAT; and (iii) other customary terms and conditions.
The Company and RaySat LTD. (“RaySat”), an entity organized under the laws of the State of Israel and controlled by Mr. Yoav Leibovitch, our Chairman of the board of directors and one of our significant shareholders, are parties to a Services Agreement effective as of January 1, 2013 (as amended as of June 27, 2017, September 6, 2020, January 4, 2021 and February 24, 2022). Pursuant to this agreement, Mr. Yoav Leibovitch provides financial management, business development, presidential and management services to the Company and its subsidiaries.
On September 15, 2022, the Company’s board approved an amendment, which was approved by The Company’s shareholders on September 28, 2022, to Mr. Leibovitch’s compensation under this agreement to (i) grant Mr. Leibovitch a $2 million success bonus payable upon the Closing of the Business Combination, (ii) increase Mr. Leibovitch’s monthly fee for services provided to $100,000 per month, effective as of October 1, 2022, increase Mr. Leibovitch’s yearly bonus such that the yearly bonus shall be 2% of the incremental year-over-year growth of the shareholders’ equity in the consolidated financial statements of the Company and increase Mr. Leibovitch’s annual bonus such that the annual bonus shall be 2% of the incremental year- over-year growth of revenues in the consolidated financial statements of the Company.
On October 19, 2023, upon recommendation of the Company’s board and compensation committee, our shareholders approved a one-time special success bonus of up to $1 million in the aggregate to our Executive Chairman of the Board, Mr. Yoav Leibovitch, in connection with the MDA Agreement (See note 3). The MDA bonus is to be paid in nine installments. Each of the special success bonus amounts relates to proceeds we have received and expect to receive with respect to the MDA Agreement during the relevant month. The MDA bonus shall not be paid if for any reason whatsoever, whether due to default by the Company or otherwise, we do not actually receive the relevant proceeds with respect to the MDA Agreement.
For the year ended December 31, 2023:
|
Name |
Position |
Scope of
Position
|
Holding
Rate
|
Salary, bonuses and
related expenses
|
Expected
Bonus
|
Share-
Based Payments
|
||||||
Nir Barkan
|
Acting CEO
|
Full Time
|
0.25%
|
303
|
160
|
129
|
||||||
Ilan Gat (Simona Gat)
|
Former president and COO
|
Full Time
|
19.47%
|
605
|
-
|
39
|
||||||
Raysat (Yoav Leibovitch)
|
Chairman
|
Full Time
|
26.35%
|
1,750
|
450
|
39
|
Name |
Position
|
Scope of
Position
|
Holding
Rate
|
Salary, bonuses and
related expenses
|
Expected
Bonus
|
Share-
Based Payments
|
||||||
Ilan Gat (Simona Gat)
|
President and COO
|
Full Time
|
19.8%
|
660
|
40
|
39
|
||||||
Raysat (Yoav Leibovitch)
|
Chairman
|
Full Time
|
27.04%
|
5,065
|
60
|
39
|
|
For the year ended
December 31
|
|||||||
|
2023
|
2022
|
||||||
Assets
|
||||||||
Contract assets (Jet Talk)
|
-
|
1,679
|
||||||
Jet Talk
|
75
|
157
|
||||||
Total Assets
|
75
|
1,836
|
||||||
Labilities
|
||||||||
Raysat Israel LTD.
|
550
|
160
|
||||||
Ilan Gat Engineers LTD
|
-
|
95
|
||||||
Former CEO
|
-
|
100
|
||||||
Current CEO
|
190
|
-
|
||||||
Jet Talk
|
-
|
53
|
||||||
Total Liabilities
|
740
|
408
|
December 31, 2023
|
December 31, 2022
|
|||||||
Cash
|
13,979
|
11,934
|
||||||
Trade accounts receivables
|
2,260
|
1,295
|
||||||
Other accounts receivable
|
2,053
|
2,166
|
||||||
Promissory Notes
|
20,000
|
-
|
||||||
Other long term receivables
|
2,000
|
-
|
||||||
FPA
|
-
|
40,852
|
||||||
Contract assets
|
4,091
|
5,035
|
||||||
Total
|
44,383
|
61,282
|
a. |
Currency risk:
|
F - 55
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 15 - FINANCIAL INSTRUMENTS – RISK MANAGEMENT (CONT.):
a. |
Currency risk (cont.):
|
December 31, 2023
|
||||||||||||||||||||
NIS
|
EUR
|
GBP
|
USD
|
Total
|
||||||||||||||||
Assets:
|
||||||||||||||||||||
Cash and cash equivalents
|
1,120
|
1,372
|
235
|
11,252
|
13,979
|
|||||||||||||||
Trade receivables
|
-
|
55
|
-
|
2,205
|
2,260
|
|||||||||||||||
Prepaid expenses and other account receivables
|
2,036
|
17
|
2,053
|
|||||||||||||||||
Promissory Notes
|
-
|
-
|
-
|
20,000
|
20,000
|
|||||||||||||||
Other long-term receivables
|
-
|
-
|
-
|
2,000
|
2,000
|
|||||||||||||||
Contract Assets
|
-
|
-
|
128
|
3,963
|
4,091
|
|||||||||||||||
1,120
|
3,463
|
363
|
39,437
|
44,383
|
||||||||||||||||
Liabilities:
|
||||||||||||||||||||
Current liabilities:
|
||||||||||||||||||||
Current maturities long-term loans
|
- | - | - | - | - | |||||||||||||||
Liabilities in respect of leases-ST
|
(469 | ) | - | (144 | ) | (26 | ) | (639 | ) | |||||||||||
Advanced payments from MDA against future orders
|
-
|
-
|
-
|
(28,138
|
)
|
(28,138
|
)
|
|||||||||||||
Trade payables
|
(479
|
)
|
(368
|
)
|
(284
|
)
|
(247
|
)
|
(1,378
|
)
|
||||||||||
Payables and credit balances
|
(896
|
)
|
(618
|
)
|
(415
|
)
|
(5,942
|
)
|
(7,871
|
)
|
||||||||||
(1,844
|
)
|
(986
|
)
|
(843
|
)
|
(34,535
|
)
|
(38,026
|
)
|
|||||||||||
Non-current liabilities:
|
||||||||||||||||||||
Liability for IIA Royalties
|
(1,196
|
)
|
-
|
-
|
-
|
(1,196
|
)
|
|||||||||||||
Liabilities in respect of leases-LT
|
(1,558 | ) | - | (495 | ) | (14 | ) | (2,067 | ) | |||||||||||
Long term loans from banks
|
-
|
-
|
-
|
(59,792
|
)
|
(59,792
|
)
|
|||||||||||||
Net balances
|
(3,478
|
)
|
2,477
|
(975
|
)
|
(54,722
|
)
|
(56,698
|
)
|
F - 56
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
NOTE 15 - FINANCIAL INSTRUMENTS – RISK MANAGEMENT (CONT.):
b. |
Sensitivity analysis:
|
December 31, 2022
|
||||||||||||||||||||
NIS
|
EUR
|
GBP
|
USD
|
Total
|
||||||||||||||||
Assets:
|
||||||||||||||||||||
Cash and cash equivalents
|
1,281
|
640
|
607
|
9,406
|
11,934
|
|||||||||||||||
Trade receivables
|
-
|
187
|
804
|
304
|
1,295
|
|||||||||||||||
Prepaid expenses and other
|
-
|
2,149
|
-
|
17
|
2,166
|
|||||||||||||||
Derivatives FPA
|
-
|
-
|
-
|
40,852
|
40,852
|
|||||||||||||||
Contract Assets
|
-
|
-
|
3,720
|
1,315
|
5,035
|
|||||||||||||||
1,281
|
2,976
|
5,131
|
51,894
|
61,282
|
||||||||||||||||
Liabilities:
|
||||||||||||||||||||
Current liabilities:
|
||||||||||||||||||||
Current maturities long-term loans
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Liabilities in respect of leases-ST
|
(430
|
)
|
-
|
(591
|
)
|
-
|
(1,021
|
)
|
||||||||||||
Trade payables
|
(614
|
)
|
(324
|
)
|
(433
|
)
|
(88
|
)
|
(1,459
|
)
|
||||||||||
Payables and credit balances
|
(2,644
|
)
|
(942
|
)
|
(721
|
)
|
(3,322
|
)
|
(7,629
|
)
|
||||||||||
(3,688
|
)
|
(1,266
|
)
|
(1,745
|
)
|
(3,410
|
)
|
(10,109
|
)
|
|||||||||||
Non-current liabilities:
|
||||||||||||||||||||
Liability for IIA Royalties
|
(1,107
|
)
|
-
|
-
|
-
|
(1,107
|
)
|
|||||||||||||
Liabilities in respect of leases-LT
|
(1,830
|
)
|
-
|
(450
|
)
|
-
|
(2,280
|
)
|
||||||||||||
Long term loans from banks
|
-
|
-
|
-
|
(54,926
|
)
|
(54,926
|
)
|
|||||||||||||
Net balances
|
(5,344
|
)
|
1,710
|
2,936
|
(6,442
|
)
|
(7,140
|
)
|
F - 57
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
b. |
Sensitivity analysis (cont.):
|
December 31, 2023
|
December 31, 2022
|
|||||||
Linked to NIS
|
(3,478
|
)
|
(5,344
|
)
|
||||
10
|
%
|
10
|
%
|
|||||
(348
|
)
|
(534
|
)
|
|||||
Linked to EUR
|
2,477
|
1,710
|
||||||
10
|
%
|
10
|
%
|
|||||
248
|
170
|
|||||||
Linked to GBP
|
(975
|
)
|
2,936
|
|||||
10
|
%
|
10
|
%
|
|||||
(97
|
)
|
294
|
c. |
Liquidity risks:
|
F - 58
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
c. |
Liquidity risks (cont.):
|
December 31, 2023
|
Within 30 days
|
1-12 Months
|
1-5 Years
|
Total
|
||||||||||||
Liabilities in respect of leases-ST
|
172
|
467
|
-
|
639
|
||||||||||||
Trade payables
|
258
|
1,120
|
-
|
1,378
|
||||||||||||
Promissory Notes
|
-
|
20,000
|
-
|
20,000
|
||||||||||||
Other long term receivables
|
-
|
-
|
2,000
|
2,000
|
||||||||||||
Payables to related parties
|
-
|
740
|
-
|
740
|
||||||||||||
Other Accounts Payable
|
1,581
|
6,290
|
-
|
7,871
|
||||||||||||
Long term loans from banks, net
|
-
|
-
|
68,020
|
68,020
|
||||||||||||
Liabilities in respect of leases-LT
|
-
|
-
|
2,067
|
2,067
|
||||||||||||
Advanced payments from MDA against future orders
|
-
|
-
|
(28,138
|
)
|
(28,138
|
)
|
||||||||||
Liability for IIA Royalties
|
-
|
-
|
(1,107
|
)
|
(1,107
|
)
|
||||||||||
Derivatives Liabilities
|
-
|
-
|
(114
|
)
|
(114
|
)
|
||||||||||
Total
|
2,011
|
28,617
|
42,728
|
73,356
|
December 31, 2022
|
Within 30 days
|
1-12 Months
|
1-5 Years
|
Total
|
||||||||||||
Liabilities in respect of leases-ST
|
269
|
752
|
-
|
1,021
|
||||||||||||
Trade payables
|
251
|
1,209
|
-
|
1,460
|
||||||||||||
Payables to related parties
|
-
|
-
|
-
|
-
|
||||||||||||
Other Accounts Payable
|
3,534
|
4,309
|
-
|
7,843
|
||||||||||||
Long term loans from banks, net
|
-
|
-
|
77,543
|
77,543
|
||||||||||||
Liabilities in respect of leases-LT
|
-
|
-
|
2,280
|
2,280
|
||||||||||||
Loan from Shareholder
|
-
|
-
|
-
|
-
|
||||||||||||
Derivatives Liabilities
|
-
|
-
|
20,305
|
20,305
|
||||||||||||
Total
|
4,054
|
6,270
|
100,128
|
110,452
|
F - 59
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
d. |
Fair value of financial instruments measured at fair value on a periodic basis:
|
Level |
December 31, 2023 |
December 31, 2022 |
||||||||||
Financial Liabilities:
|
||||||||||||
Warrants
|
3
|
-
|
-
|
|||||||||
SPAC Public Warrant
|
1
|
-
|
286
|
|||||||||
SPAC Private Warrant
|
2
|
-
|
121
|
|||||||||
Advanced payments from MDA against future orders
|
3 | 28,138 |
-
|
|||||||||
Price Adjustment shares
|
3
|
114
|
19,898
|
|||||||||
Total
|
28,252 |
20,305
|
e. |
Classification of financial instruments by fair value hierarchy:
|
Warrants
|
||||
Balance at January 1, 2022
|
1,392
|
|||
Exercise of warrants to shares
|
(397
|
)
|
||
Exercise of warrants to cash (adjustment to other accounts payables)
|
(800
|
)
|
||
Changes in fair value recognized in finance expenses
|
(195
|
)
|
||
Balance at December 31, 2022
|
-
|
|||
Exercise of warrants to shares
|
-
|
|||
Exercise of warrants to cash (adjustment to other accounts payables)
|
-
|
|||
Changes in fair value recognized in finance expenses
|
-
|
|||
Balance at December 31, 2023
|
-
|
F - 60
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
f. |
SPAC warrants:
|
SPAC Warrants
|
||||
Balance at December 31, 2022
|
407
|
|||
Issuance of warrant (SPAC transactions)
|
-
|
|||
Changes in fair value recognized in finance expenses
|
(407
|
)
|
||
Exercise of warrants
|
-
|
|||
Balance at December 31, 2023
|
-
|
g. |
Price Adjustment shares:
|
F - 61
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
g. |
Price Adjustment shares (cont.):
|
F - 62
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
g. |
Price Adjustment shares (cont.):
|
PAS
|
||||
Balance on December 31, 2022
|
19,898
|
|||
Changes in fair value recognized in finance expenses
|
(19,784
|
)
|
||
Balance on December 31, 2023
|
114
|
a. |
Breakdown of other long-term liabilities:
|
|
December 31,
2023
|
December 31,
2022
|
||||||
Liability for IIA Royalties (See Note 16(b) below)
|
1,196
|
1,107
|
||||||
Alta settlement (See note 19)
|
300
|
-
|
||||||
1,496
|
1,107
|
b. |
Liability for royalties payable:
|
b. |
Liability for royalties payable (cont.):
|
|
|
December 31,
2023
|
December 31,
2022
|
||||||
|
||||||||
At January 1
|
1,107
|
1,368
|
||||||
Principal Payments
|
(11
|
)
|
(429
|
)
|
||||
Amounts recognized as an offset from research and development expenses
|
(113
|
)
|
(210
|
)
|
||||
Revaluation of the liability
|
213
|
378
|
||||||
As of December 31
|
1,196
|
1,107
|
F - 64
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
At January 1, 2022
|
-
|
|||
FPA (SPAC transactions)- Assets
|
42,502
|
|||
FPA (SPAC transactions)- Liability
|
(13,306
|
)
|
||
FPA (SPAC transactions) net
|
29,196
|
|||
Revaluation as of 21.11.2022
|
(36,692
|
)
|
||
Issuance of shares in 21.11.2022
|
49,998
|
|||
Revaluation as of 31.12.2022
|
(1,650
|
) | ||
As of December 31, 2022 | 40,852 | |||
Cash received |
(10,026 |
) | ||
Revaluation as of October 2023
|
(37,408 | ) | ||
Termination
|
(6,582
|
) | ||
As of December 31, 2023
|
-
|
F - 65
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
a. |
Ordinary share:
|
b. |
SPAC merger:
|
c. |
Share Option Plan:
|
F - 66
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
c. |
Share Option Plan (cont.):
|
|
F - 67
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
c. |
Share Option Plan (cont.):
|
|
Options Outstanding
|
Options Exercisable
|
|||||||||||||
Number Outstanding on
December 31, 2023
(in thousands)
|
Weighted Average
Remaining Contractual Life |
Number Exercisable on
December 31, 2023
(in thousands)
|
Exercise Price
|
|||||||||||
Years
|
USD
|
|||||||||||||
768
|
1.06
|
768
|
0.0001
|
|||||||||||
563
|
0.17
|
563
|
0.536
|
|||||||||||
260
|
4.46
|
260
|
0.550
|
|||||||||||
1,162
|
5.26
|
1,095
|
1.102
|
|||||||||||
3,462
|
7.1
|
485
|
2.5
|
|||||||||||
6,215
|
3,171
|
|
2023
|
2022
|
||||||||||||||
|
Number of Options
|
Weighted Average Exercise Price
|
Number of Options
|
Weighted Average Exercise Price
|
||||||||||||
|
USD |
|
USD |
|
||||||||||||
Options outstanding at the beginning of year:
|
7,297
|
1.76
|
7,710
|
1.72
|
||||||||||||
Changes during the year:
|
||||||||||||||||
Granted
|
-
|
-
|
1,405
|
2.50
|
||||||||||||
Exercised
|
38
|
0.68
|
226
|
0.42
|
||||||||||||
Forfeited
|
1,044
|
2.38
|
1,592
|
0.22
|
||||||||||||
Options outstanding at end of year
|
6,215
|
1.67
|
7,297
|
1.76
|
||||||||||||
Options exercisable at year-end
|
3,171
|
0.90
|
3,169
|
0.87
|
F - 68
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
c. |
Share Option Plan (cont.):
|
|
|
Number of RSUs
|
|||
Outstanding at beginning of year
|
-
|
|||
Granted
|
7,808,280
|
|||
Vested
|
(902,753
|
)
|
||
Forfeited
|
(1,686,426
|
)
|
||
Unvested as of December 31, 2023
|
5,219,101
|
a. |
The Company’s UK subsidiaries had signed several agreements with the European Space Agency (hereinafter: “ESA” or “The Agency”) as part of the Agency’s ARTES programs. The objectives of ARTES programs are to ensure the readiness of the industry to respond to commercial opportunities by focusing the activities on technological innovation in equipment, systems, and applications for satellite communication, resulting in products ready for future exploitation within either the commercial or institutional market. Accordingly, the Agency had agreed to participate in the funding of the development of an integrated chip sets for several industries, which includes both hardware and software. The Agency’s participation varies between 50%-75% of the cost, depending on the nature of the engagement.
The grants are recognized in the statement of operations as a reduction of research and development expenses and are recognized when the Company is entitled, on the basis of the accumulation of expenses for which the grants are received.
The Agency does not require any future royalties nor any ownership of the Intellectual Property (“IP”) resulting from the development which is owned by the Company’s UK subsidiaries, however, the agreement do stipulates that the IP will be available to the Agency on a free, worldwide license for its own requirements, The Agency can require the Company to license the IP to certain bodies that are part of specified Agency programs, for the Agency’s own requirements on acceptable commercial terms and can also require the Company to license the IP to any other third party for purposes other than the Agency’s requirements subject to the approval of the Company that those other purposes do not contradict its commercial interests. Grants received from ESA are recognized in the statement of operations as a reduction of the research and development expenses and are recognized when the Company is entitled, on the basis of the accumulation of expenses for which the grants are received.
|
F - 69
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
b. |
The Israeli Subsidiary also participated in programs that were financed by the Government of Israel for supporting research and development activities. As of December 31, 2022, the Israeli Subsidiary had obtained grants from the IIA to finance its research and development programs in the aggregate of $6,334 thousand, of which $3,289 bear royalties.
In return for financing these programs, the Israeli Subsidiary committed to pay the IIA royalties of 3%-4% of total sales of products from revenues related to these programs. The royalties will be paid up to a maximum amount representing 100% of total grants received and are linked to the U.S. dollar exchange rate with the addition of an annual dollar interest rate. As of December 31, 2022, and December 31, 2020 the Israeli Subsidiary has accumulated liability in respect of royalties to the IIA in the amount of $314 and $916 thousand, respectively, representing 3%- 4% of revenues.
As of December 31, 2023, and December 31, 2022, the Israeli Subsidiary has a contingent liability to IIA in the amount of $1,107 and $1,368, respectively, based on discounted future royalties at an interest rate of 20%, respectively.
|
F - 71
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
The Company is organized as one operating segment.
1. |
Transactions with main customers:
|
For the year ended December 31,
|
||||||||||||||||||||||||
2023 | 2022 | 2021 | ||||||||||||||||||||||
|
USD thousands
|
%
|
USD thousands
|
%
|
USD thousands
|
%
|
||||||||||||||||||
Jet Talk
|
-
|
-
|
-
|
-
|
3,116
|
14
|
%
|
|||||||||||||||||
Airbus
|
188
|
2
|
%
|
318
|
3
|
%
|
3,256
|
15
|
%
|
|||||||||||||||
Telesat
|
4,250
|
40
|
%
|
5,326
|
50
|
%
|
8,400
|
39
|
%
|
|||||||||||||||
iDirect
|
2,605
|
24
|
%
|
489
|
5
|
%
|
2,074
|
10
|
%
|
|||||||||||||||
Trustcom
|
-
|
0
|
%
|
1,108
|
10
|
%
|
-
|
-
|
||||||||||||||||
MDA
|
1,497
|
14
|
%
|
1,907
|
18
|
%
|
-
|
-
|
||||||||||||||||
Confidential Customer
|
1,309
|
12
|
%
|
1,162
|
11
|
%
|
-
|
-
|
2. |
Geographical areas:
|
US & Canada
|
UK
|
Other
|
Consolidated
|
|||||||||||||||||||||||||||||||||||||||||||||
2023
|
2022
|
2021
|
2023
|
2022
|
2021
|
2023
|
2022
|
2021
|
2023
|
2022
|
2021
|
|||||||||||||||||||||||||||||||||||||
Revenues
|
8,446
|
9,310
|
13,196
|
732
|
1,070
|
7,325
|
1,552
|
246
|
1,199
|
10,730
|
10,626
|
21,720
|
|
December 31, 2023
|
December 31, 2022
|
December 31, 2021
|
|||||||||
Salaries and related expenses
|
2,861
|
3,556
|
6,764
|
|||||||||
Materials and models
|
2,276
|
707
|
1,516
|
|||||||||
Depriciation
|
34
|
21
|
56
|
|||||||||
Chip Development tools and Subcontractors
|
767
|
214
|
507
|
|||||||||
Total
|
5,938
|
4,498
|
8,843
|
For the year ended
|
||||||||||||
|
December 31, 2023
|
December 31, 2022
|
December 31, 2021
|
|||||||||
Salaries and related expenses, including Stock Based Compensation
|
23,450
|
21,923
|
18,810
|
|||||||||
Chip pre-production and Development tools
|
9,917
|
7,214
|
12,936
|
|||||||||
Government support and grants
|
(4,241
|
)
|
(12,295
|
)
|
(13,802
|
)
|
||||||
Total
|
29,126
|
16,842
|
17,944
|
F - 73
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
For the year ended
|
||||||||||||
|
December 31, 2023
|
December 31, 2022
|
December 31, 2021
|
|||||||||
Salaries and related expenses
|
2,866
|
2,335
|
1,752
|
|||||||||
Total
|
2,866
|
2,335
|
1,752
|
For the year ended
|
||||||||||||
|
December 31, 2023
|
December 31, 2022
|
December 31, 2021
|
|||||||||
Salaries and related expenses
|
5,925
|
8,175
|
3,233
|
|||||||||
Depreciation and overheads
|
93
|
132
|
240
|
|||||||||
Expected Credit Loss (a)
|
1,876
|
-
|
-
|
|||||||||
Other expenses (b)
|
6,667
|
942
|
262
|
|||||||||
Total
|
14,561
|
9,249
|
3,735
|
(a) |
Write off of a contract asset relating to Jet-Talk contract asset balance, as the Company does not believe it can benefit from the remaining asset due to certain disagreement between the parties, which are under discussion and expected to be resolved in the near future.
|
(b) |
In 2023 expenses occurred following the Alta settlement of $2.3 million (see Note 19) and new D&O Insurance policy expenses.
|
F - 74
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
Note
|
October 27, 2022
|
||||||
Price Adjustment Shares
|
212,675
|
||||||
Issuance of shares
|
149,657
|
||||||
Private Warrants
|
15
|
1,681
|
|||||
Public Warrants
|
15
|
2,203
|
|||||
PIPE Warrants
|
15
|
22
|
|||||
Net Liability of Business Combination
|
687
|
||||||
Forward Purchase Agreement- Liabilities
|
17
|
13,306
|
|||||
380,231
|
|||||||
Total Cash
|
(7,813
|
)
|
|||||
Forward Purchase Agreement- Assets
|
17
|
(42,502
|
)
|
||||
(50,315
|
)
|
||||||
Other Listing Expenses
|
3,410
|
||||||
Total
|
333,326
|
Quantity
|
Price
|
Total Amount
|
||||||||||||||
Price Adjustment Shares
|
27,500
|
7.73
|
212,575
|
2
|
||||||||||||
Premium- SPAC shares
|
14,800
|
10.11
|
149,628
|
3
|
||||||||||||
Warrants
|
18,630
|
0.22
|
4,099
|
1
|
||||||||||||
Forward Purchase Agreement- Liabilities
|
1,605
|
8.29
|
13,305
|
1
|
||||||||||||
Forward Purchase Agreement- Assets
|
42,502
|
4
|
F - 75
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
(1) |
Price based on the public price in the closing date.
|
(2) |
See note 15.
|
(3) |
Price based on the market price prior to the SPAC transaction.
|
(4) |
See note 17.
|
A. |
Tax base:
|
F - 76
SATIXFY COMMUNICATIONS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of USD)
B. |
Uncertain tax position:
|
C. |
Tax losses:
|
D. |
Tax assessments:
|
For the year ended December 31
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Calculation of basic earnings per share:
|
||||||||||||
Net loss
|
(29,715
|
)
|
(397,789
|
)
|
(17,050
|
)
|
||||||
Loss attributed to ordinary shareholders in USD
|
(29,715
|
)
|
(397,789
|
)
|
(17,050
|
)
|
||||||
Weighted average number of ordinary shares
|
80,974,653
|
30,030,805
|
18,732,473
|
|||||||||
Basic and diluted loss per share attributed in USD
|
(0.37
|
)
|
(13.25
|
)
|
(0.91
|
)
|
F - 77
•
|
amendments to our articles of association;
|
•
|
appointment or termination of our auditors;
|
•
|
appointment of external directors;
|
•
|
approval of certain related party transactions;
|
•
|
increases or reductions of our authorized share capital;
|
•
|
mergers; and
|
•
|
the exercise of our board of director’s powers by a general meeting if our board of directors is unable to exercise its powers and the
exercise of any of its powers is required for our proper management.
|
|
•
|
a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s
award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can
be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail
the above mentioned events and amount or criteria;
|
|
•
|
reasonable litigation expenses, including attorneys’ fees, incurred by the office holder as a result of an investigation or proceeding
instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial
liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an
offense that does not require proof of criminal intent;
|
|
•
|
reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings instituted
against him or her by the company, on its behalf or by a third party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal
intent; and
|
|
•
|
expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative
proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.
|
|
•
|
a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to
believe that the act would not prejudice the company;
|
|
•
|
a breach of the duty of care to the company or to a third party, including a breach arising out of the negligent conduct of the office holder;
|
|
•
|
a financial liability imposed on the office holder in favor of a third party;
|
|
•
|
a financial liability imposed on the office holder in favor of a third party harmed by a breach in an administrative proceeding; and
|
|
•
|
expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative
proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.
|
|
•
|
a breach of the duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not prejudice the company;
|
|
•
|
a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the
office holder;
|
|
•
|
an act or omission committed with intent to derive illegal personal benefit; or
|
|
•
|
a fine or forfeit levied against the office holder.
|
|
•
|
in whole and not in part;
|
|
•
|
at a price of $0.01 per warrant;
|
|
•
|
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
|
|
•
|
if, and only if, the last reported sale price of the Ordinary Shares for any 20 trading days within a 30-trading day period ending on
the third trading day prior to the date on which we send the notice of redemption to the warrant holders (which we refer to as the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares
issuable upon exercise or the exercise price of a warrant as described under the heading “-—Anti-dilution adjustments” ).
|
|
•
|
in whole and not in part;
|
|
•
|
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their
warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of the Ordinary Share (as defined below) except as
otherwise described below;
|
|
•
|
if, and only if, the Reference Value (as defined above under “— Redemption of warrants when the price
per SatixFy Ordinary Share equals or exceeds $18.00”) equals or exceeds $10.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading
“-—Anti-dilution adjustments”; and
|
|
Fair Market Value of Shares of SatixFy Ordinary Shares
|
|||||||||||||||||||||||||||||||||||
|
≤10.00
|
11.00
|
12.00
|
13.00
|
14.00
|
15.00
|
16.00
|
17.00
|
≥18.00
|
|||||||||||||||||||||||||||
60 months
|
0.261
|
0.281
|
0.297
|
0.311
|
0.324
|
0.337
|
0.348
|
0.358
|
0.361
|
|||||||||||||||||||||||||||
57 months
|
0.257
|
0.277
|
0.294
|
0.310
|
0.324
|
0.337
|
0.348
|
0.358
|
0.361
|
|||||||||||||||||||||||||||
54 months
|
0.252
|
0.272
|
0.291
|
0.307
|
0.322
|
0.335
|
0.347
|
0.357
|
0.361
|
|||||||||||||||||||||||||||
51 months
|
0.246
|
0.268
|
0.287
|
0.304
|
0.320
|
0.333
|
0.346
|
0.357
|
0.361
|
|||||||||||||||||||||||||||
48 months
|
0.241
|
0.263
|
0.283
|
0.301
|
0.317
|
0.332
|
0.344
|
0.356
|
0.361
|
|||||||||||||||||||||||||||
45 months
|
0.235
|
0.258
|
0.279
|
0.298
|
0.315
|
0.330
|
0.343
|
0.356
|
0.361
|
|||||||||||||||||||||||||||
42 months
|
0.228
|
0.252
|
0.274
|
0.294
|
0.312
|
0.328
|
0.342
|
0.355
|
0.361
|
|||||||||||||||||||||||||||
39 months
|
0.221
|
0.246
|
0.269
|
0.290
|
0.309
|
0.325
|
0.340
|
0.354
|
0.361
|
|||||||||||||||||||||||||||
36 months
|
0.213
|
0.239
|
0.263
|
0.285
|
0.305
|
0.323
|
0.339
|
0.353
|
0.361
|
|||||||||||||||||||||||||||
33 months
|
0.205
|
0.232
|
0.257
|
0.280
|
0.301
|
0.320
|
0.337
|
0.352
|
0.361
|
|||||||||||||||||||||||||||
30 months
|
0.196
|
0.224
|
0.250
|
0.274
|
0.297
|
0.316
|
0.335
|
0.351
|
0.361
|
|||||||||||||||||||||||||||
27 months
|
0.185
|
0.214
|
0.242
|
0.268
|
0.291
|
0.313
|
0.332
|
0.350
|
0.361
|
|||||||||||||||||||||||||||
24 months
|
0.173
|
0.204
|
0.233
|
0.260
|
0.285
|
0.308
|
0.329
|
0.348
|
0.361
|
|||||||||||||||||||||||||||
21 months
|
0.161
|
0.193
|
0.223
|
0.252
|
0.279
|
0.304
|
0.326
|
0.347
|
0.361
|
|||||||||||||||||||||||||||
18 months
|
0.146
|
0.179
|
0.211
|
0.242
|
0.271
|
0.298
|
0.322
|
0.345
|
0.361
|
|||||||||||||||||||||||||||
15 months
|
0.130
|
0.164
|
0.197
|
0.230
|
0.262
|
0.291
|
0.317
|
0.342
|
0.361
|
|||||||||||||||||||||||||||
12 months
|
0.111
|
0.146
|
0.181
|
0.216
|
0.250
|
0.282
|
0.312
|
0.339
|
0.361
|
|||||||||||||||||||||||||||
9 months
|
0.090
|
0.125
|
0.162
|
0.199
|
0.237
|
0.272
|
0.305
|
0.336
|
0.361
|
|||||||||||||||||||||||||||
6 months
|
0.065
|
0.099
|
0.137
|
0.178
|
0.219
|
0.259
|
0.296
|
0.331
|
0.361
|
|||||||||||||||||||||||||||
3 months
|
0.034
|
0.065
|
0.137
|
0.150
|
0.197
|
0.243
|
0.286
|
0.326
|
0.361
|
|||||||||||||||||||||||||||
0 months
|
–
|
–
|
0.042
|
0.115
|
0.179
|
0.233
|
0.281
|
0.323
|
0.361
|
|||||||||||||||||||||||||||
9 months
|
0.090
|
0.125
|
0.162
|
0.199
|
0.237
|
0.272
|
0.305
|
0.336
|
0.361
|
1) SatixFy UK Limited
|
|
and | |
2) Nir Barkan |
1) |
SatixFy UK Limited of Spectrum Point, 279 Farnborough Road, Farnborough, Hampshire, GU14 7LS, United Kingdom (“the Company")
|
2)
|
Nir Barkan, of Chelsea Court, 17 Melville Place, London, N1 8 NE (“you")
|
1. |
THE APPOINTMENT
|
1.1 |
Your employment with the Company as Acting Chief Executive Officer commenced on 1st June 2023 and you shall continue to serve the Company until the Appointment is terminated pursuant to and in accordance with Clause 1.3 or
Clause 14 below.
|
1.2 |
For statutory purposes, your period of continuous employment began on the Commencement Date. Subject to Clause 1.3, you or the Company can terminate the employment by giving the other not less than 60 days(2 months)’ written notice.
|
1.3 |
Your first three months of employment will be treated as a probationary period. Your employment may be terminated by you or the Company on one months notice in writing at any time during or at the end of this period. The Company reserves
the right to extend the probationary period, and in such circumstances, your notice period will remain at one week.
|
2. |
RESPONSIBILITIES AND DUTIES
|
2.1 |
During the Appointment you shall:
|
2.1.1 |
unless prevented by illness or injury, devote the whole of your time, attention and abilities to the business of the Company and any Associated Company;
|
2.1.2 |
diligently exercise such powers and perform such duties as may from time to time be assigned to you by the Company together with such person or persons as the Company may appoint to act jointly with you;
|
2.1.3 |
comply with all reasonable and lawful directions given to you by the Company;
|
2.1.4 |
promptly make such reports to your line manager in connection with the affairs of the Company or any Associated Company on such matters and at such times as are reasonably required;
|
2.1.5 |
report your own wrongdoing and any wrongdoing or proposed wrongdoing of any other employee or director of the Company or any Associated Company to your line manager immediately on becoming aware of it;
|
2.1.6 |
not do, or permit to be done anything to prejudice the interests of, or cause loss or injury to the Company;
|
2.1.7 |
use your best endeavours to promote, protect, develop and extend the business of the Company or any Associated Company; and
|
2.1.8 |
consent to the Company monitoring and recording any use that you make of the Company's electronic communications systems for the purpose of ensuring that the Company's rules are being complied with and for legitimate business purposes.
|
2.2 |
You shall comply with the Company's policies and procedures as communicated from time to time.
|
2.3 |
You shall not during your employment by the Company be directly or indirectly engaged or concerned or interested in any other trade or business or the setting up of any business which is similar to or in competition with the business
carried on by the Company or any Associated Company or any part of such business without the written consent of the Company. This shall not prevent you from holding an investment by way of shares or other securities of not more than 5% of
the total issued share capital of any company, whether or not it is listed or dealt in on a recognised stock exchange.
|
2.4 |
It is expected that you shall devote your whole time and attention to the Company, or any Associated Company, during working hours and will not do anything outside of working hours that may prejudice or inhibit your ability or capability
to perform your role with the Company. Therefore, if you intend to take on employment or other work outside of your normal working hours with the Company, you must first obtain the written permission of the Company. Such written
permission to not be unreasonably withheld.
|
2.5 |
You shall comply with all rules, policies and procedures of the Company as set out in the Employee Handbook or otherwise published to employees. The Employee Handbook and company policies do not form part of this Agreement and the
Company may amend the same from time to time.
|
3. |
Warranties
|
3.1 |
You represent and warrant to the Company that, by entering into this agreement or performing any of your obligations under it, you will not be in breach of any court order or any express or implied terms of any contract or other
obligation binding on you and undertake to indemnify the Company against any claims, costs, damages, liabilities or expenses which the Company may incur as a result if you are in breach of any such obligations.
|
3.2 |
You represent and warrant to the Company that prior to commencing your employment you have disclosed to the Company and throughout the course of your employment you will disclose to the Company any criminal convictions, county court
judgements or any other civil or criminal matters or any circumstances that may, in the reasonable opinion of the Company, prevent, hinder, affect or undermine your ability to undertake any duties that you has been assigned by the employer.
|
3.3 |
You represent and warrant to the Company that there are no matters of which you are aware that would affect the Company’s willingness to enter into the terms of this Agreement.
|
3.4 |
You represent and warrant to the Company that the details of your skills, qualifications and experience as presented to the Company as part of the process to recruit you for this role are accurate.
|
3.5 |
You represent and warrant that you are entitled to work in the United Kingdom without any additional approvals and will notify the Company immediately if you cease to be so entitled during the Appointment.
|
4. |
HOURS OF WORK
|
4.1 |
The normal business hours of the Company are five days a week, Monday to Friday from 9:00 a.m. to 5.30 p.m. with half an hour’s break for lunch.
|
4.2 |
You agree that until further notice the limit on working hours specified under Regulation 4(1) of the Working Time Regulations shall not apply to you. You acknowledge that your monthly salary as defined hereinafter covers the overall
working hours that are required to fulfil your duties in your position including additional working hours and working in irregular hours.
|
4.3 |
You agree to record the number of your working hours in a manner and using the system that is designated by the Company for this purpose and in accordance with the Company policies and guidelines.
|
5. |
PLACE OF WORK
|
5.1 |
Your place of work will be WFH or such other places as the Company may continue to operate from time to time.
|
5.2 |
The Company may require you to work from any of its premises from time to time or at the premises of a customer depending upon the needs of the business, or at such places as the Company may from time to time require.
|
5.3 |
You agree to travel on the Company's or any Group Company's business (both within the United Kingdom or abroad) as may be required for the proper performance of your duties under the Appointment.
|
5.4 |
During the Appointment you shall not be required to work outside the United Kingdom for any continuous period of more than one month.
|
6. |
REMUNERATION
|
6.1 |
Subject to and in consideration of fulfilling your duties the Company shall pay you during the continuation of the Appointment a basic salary of 244,134GBP per annum less Income Tax and National Insurance Contributions. Your basic salary
shall be deemed to accrue from day to day and (unless otherwise agreed in writing) will be payable by equal monthly instalments on the 1st of each month in arrears.
|
6.2 |
Your salary will be reviewed once a year (without any commitment to increase).
|
6.3 |
The Company shall be entitled to deduct from any salary due to you at any time under the terms of this Agreement any monies of whichever nature which are owed by you to the Company.
|
7. |
PRIVATE MEDICAL, LIFE ASSURANCE IN SERVICE, CRITICAL ILLNESS AND LONG-TERM DISABILITY INSURANCE
|
7.1.1 |
You are entitled to membership of such private medical insurance scheme, long-term disability insurance scheme, critical illness scheme and death in service benefit (“the Schemes”) as the Company may from time to time decide to maintain
for the benefit of its employees, subject to the rules of such schemes as imposed by the provider from time to time. Any benefits payable under any such scheme will be subject to the rules of the scheme and the terms of any applicable
insurance policy, and are conditional on you complying with and satisfying any requirements of the insurers.
|
7.1.2 |
The Company shall not have any liability to pay any benefit to you under any scheme unless it receives payment of the benefit from the insurer under the scheme.
|
7.1.3 |
Participation in the Schemes is subject to:
|
7.1.3.1 |
the terms of the Schemes, as amended from time to time;
|
7.1.3.2 |
the rules of the relevant insurance provider, as amended from time to time; and
|
7.1.3.3 |
you satisfying the normal underwriting requirements of the relevant provider and the premium being at a rate which the Company considers reasonable.
|
7.1.4 |
If a provider refuses for any reason to provide any of the Schemes to you the Company shall not be liable to provide you any replacement benefit of the same or similar kind or to pay any compensation in lieu of such benefit.
|
7.1.5 |
The Company in its sole and absolute discretion reserves the right to vary or amend any of the Schemes (including the level of cover provided by the Schemes) at any time on reasonable notice to you.
|
8. |
PENSION
|
8.1 |
The Company provides access to a Group Personal Pension Plan (GPPP) in accordance with the rules of such scheme or such other pension provider as may be nominated by the Company from time to time for your benefit. The Company reserves
the right to discontinue or replace such scheme with such other scheme it considers fit.
|
8.2 |
You will become an active member of the Company’s GPPP, subject to eligibility rules set by the Department of Work and Pensions, within the third calendar month of joining the Company.
|
8.3 |
The Company will make contributions on your behalf subject to your making a minimum contribution of 3% of your basic salary as notified to you upon the joining of the Pension Plan. Any contributions shall be payable in equal monthly
instalments. Your contributions shall be made by way of deduction through your basic monthly salary.
|
9. |
HOLIDAYS AND HOLIDAY PAY
|
9.1 |
The Company’s holiday year runs from 1 January to 31 December and your paid holiday will be based on an annual entitlement of 24 days, plus recognised public and bank holidays. The holidays during the first year will be accrued on a
pro-rata basis.
|
9.2 |
You will be entitled to carry over up to 8 days annual leave to the following holiday year.
|
9.3 |
Three days of the annual entitlement must be taken during the Christmas holiday period as part of planned holiday shut-down. The Company will announce the dates of these three nominated Christmas holidays as early as possible in each
year.
|
9.4 |
You must give the Company not less than two weeks’ notice, save in exceptional circumstances, for any requests for annual leave. You are not entitled to take more than 10 days as consecutive holiday unless agreed by the Company.
|
9.5 |
The entitlement to holiday pay (and on the termination of your employment to holiday pay in lieu of holiday) accrues pro rata from the commencement of your employment until the end of the current holiday year and thereafter in each
subsequent holiday year.
|
9.6 |
Upon the termination of your employment, your entitlement to accrued holiday pay shall be calculated on a pro rata basis in respect of each completed month of service in the holiday year in which your employment terminates and the
appropriate amount shall be paid to you provided that if you shall have taken more days holiday than your accrued entitlement the Company is hereby authorised to make an appropriate deduction in respect thereof from your final salary
payment.
|
10. |
SICK PAY AND ABSENCE
|
10.1 |
If you are unable to attend work for any reason and your absence has not previously been authorised by the Company you must inform your line manager and the reasons for it by 9.00 a.m. on each working day of absence and keep the Company
informed as to the expected duration of your absence.
|
10.2 |
For any period of sickness of one day or more you must complete a self-certification form on returning to work.
|
10.3 |
If you are absent from work due to sickness or injury which continues for more than seven days (including weekends) you must provide the Company with a medical certificate by the eighth day of sickness or injury. Thereafter medical
certificates must be provided to the Company to cover any continued absence and the Company reserves the right to require you to be examined at any time by an independent doctor at its expense. You will agree to the release of your medical
records to any independent doctor appointed by the Company for the purposes of undertaking a medical report. You also agree to authorise such doctor to report his findings and recommendations to the Company and in addition you agree to
authorise your own doctor to supply details of your medical condition to the doctor appointed by the Company.
|
10.4 |
If you are incapable of working by reason of injuries sustained wholly or partly as a result of the actionable negligence, nuisance or breach of any statutory duty on the part of any third party, all payments made to you by the Company
under this clause shall to the extent that compensation is recoverable from that third party constitute loans by the Company to you which should be repaid when and to the extent that you recover compensation for loss of earnings from that
third party by action or otherwise.
|
10.5 |
During absence through illness (including mental disorder), injury or other incapacity, you may be eligible to receive pay whilst off sick at the Company’s discretion in accordance with company policy at such time. For the avoidance of
doubt, any sickness payments will include statutory sickness payments and are subject to you having completed at least 12 months’ continuous employment with the Company, prior to the period of absence.
|
10.6 |
If you fail to notify the Company of your absence or attend an independent medical examination in accordance with the procedures set out above and or unable to give a satisfactory explanation for your absence, the Company reserves the
right to withhold any sickness payments due to you.
|
10.7 |
If you are incapable of working due to sickness and are being paid either company or statutory sick pay, you are not allowed to perform any paid duties in alternative employment or voluntary work. Any employee found in breach of this
rule will be considered to have performed an act of gross misconduct which may result in dismissal.
|
11. |
EXPENSES
|
11.1 |
The Company will reimburse all expenses necessarily incurred by you in the proper performance of your duties, provided that the Company has agreed to you incurring the expenses. You must also provide the Company with evidence of actual
payment of the expenses as the Company may reasonably require.
|
12. |
CONFIDENTIALITY
|
12.1 |
You shall not during your employment by the Company or after the termination of your employment without the prior written consent of the Company use for your own purposes, or divulge to any third party, or otherwise make use of any
Confidential Information of which you shall become possessed, relating in any way to the business of the Company or its techniques, systems or know-how.
|
12.2 |
You shall, during your employment by the Company, use your best endeavours to prevent the publication or disclosure of Confidential Information.
|
12.3 |
Except to the extent necessary in the proper course of your employment or as required by law, you shall not at any time during or after your employment by the Company reproduce in any form or on any media or device or permit anyone to
reproduce any Confidential Information.
|
12.4 |
You shall not except to the extent necessary in the proper course of your employment or as required by law:
|
12.4.1 |
remove any computer disks, tapes or Materials containing any Confidential Information from the Company's premises; or
|
12.4.2 |
send by electronic means any Confidential Information.
|
12.5 |
Confidential Information which is made or received by you during your employment by the Company and all disks, tapes and Materials and any copies containing any Confidential Information shall be the property of the Company.
|
12.6 |
You shall abide by all directions of the Company from time to time and the Company's standard operating practices concerning the use, disclosure and supply of Confidential Information.
|
12.7 |
You shall not without the prior authority of the Company make any announcement, publicity or statement about the Company.
|
12.8 |
On or before termination of your employment by the Company (howsoever occasioned) or upon the Company’s written request at any stage during the course of your employment you shall:
|
12.8.1 |
deliver up to the Company all documents, Materials, disks, tapes, tangible items and any copies containing, reflecting, incorporating or based on the Company’s or any Associated Company’s Confidential Information or Intellectual
Property;
|
12.8.2 |
deliver up to the Company, any and all other documents or property belonging to the Company or any Associated Company (including but not limited to mobile telephones or other communication devices, computers, laptop computers or other
computing devices, company cars or vehicles, access cards, security passes and keys) in your possession or under your control;
|
12.8.3 |
upon the Company’s specific written request, irretrievably delete or destroy all or any of the Company’s Confidential Information or Intellectual Property that is in your possession or control and held on any personal or home computer or
other storage device ;
|
12.8.4 |
If requested to do so by the Company, certify in writing that you have complied with the requirements of this clause 12.8.
|
12.9 |
The rights and obligations under this clause shall continue in force after termination of this Agreement and shall be binding upon your representatives, but shall cease to apply to any information ordered to be disclosed by a Court of
Competent jurisdiction or otherwise as required to be disclosed by law.
|
13. |
INTELLECTUAL PROPERTY
|
14. |
TERMINATION
|
14.1 |
The Company reserves the right to pay salary only in lieu of notice given by it or you pursuant to Clause 1. Any pay in lieu of notice shall consist of a sum equivalent to your basic salary at the applicable rate at the date notice is
given for the notice period required by Clause 1 or any unexpired period of notice and shall be subject to deduction as the Company is required to make.
|
14.2 |
Notwithstanding Clause 1 the Company may terminate the Appointment forthwith without notice if:
|
14.2.1 |
you commit any repeated or continued breaches of your obligations to the Company;
|
14.2.2 |
you are convicted of any criminal offence other than an offence under the Road Traffic Acts for which imprisonment is not a sanction;
|
14.2.3 |
you are found by the Company to have committed an act of gross negligence or gross misconduct;
|
14.2.4 |
you act in any manner which in the opinion of the Company brings or is likely to bring yourself or the Company into disrepute;
|
14.2.5 |
you commit any other offence of a similar nature and gravity to the examples above, or lose your driving licence if driving forms part of your duties.
|
14.3 |
The rights of the Company under Clause 14.2 are without prejudice to any other rights it might have at law to terminate the Appointment or to accept any breach of the Agreement on the part of you having brought the Agreement to an end.
|
14.4 |
After notice of termination has been given (either by you or the Company) the Company has the right, at its discretion to require you to postpone any booked holidays and or cancel your holiday in order to work through your full notice
period
|
14.5 |
It shall be a condition of participation in any bonus or incentive scheme, including any share option scheme or restricted share plan from time to time operated by any Group Company in which you participate, or shall be entitled to
participate, that in the event of the termination of your employment with the Company due to any fault of yours or your voluntary resignation, you shall not by virtue of such termination become entitled to any damages or any additional
damages in respect of any rights or expectations of any nature you may have as a holder of share options or shares under any such schemes.
|
15. |
GARDEN LEAVE
|
15.1 |
Following service of notice to terminate the employment by either party, or if you purport to terminate your employment in breach of contract, or, if the Company so decides, in order to investigate allegations that you are guilty of
gross misconduct, the Company may by written notice require you not to perform any services (or to perform only specified services) for the Company until the termination of your employment or a specified date.
|
15.2 |
During any period of garden leave the Company shall be under no obligation to provide any work to, or vest any powers in you and you shall have no right to perform any services for the Company.
|
15.3 |
During any period of garden leave you shall:
|
15.3.1 |
continue to receive your salary and all contractual benefits in the usual way and subject to the terms of any benefit arrangement;
|
15.3.2 |
remain an employee of the Company and bound by the terms of this agreement;
|
15.3.3 |
not, without the prior written consent of the Company attend your place of work or any other premises of the Company or the premises of clients for whom you provided services in the 12-month period immediately preceding the period of
garden leave;
|
15.3.4 |
at the request of the Company, use any and all accrued but untaken annual leave that would apply or be available to you prior to the termination of your employment;
|
15.3.5 |
not without the prior written consent of the Company contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business
contact of the Company; and (except during any periods taken as holiday in the usual way) ensure that the Company knows where you will be and how you can be contacted during each working day.
|
16. |
PROTECTIVE COVENANTS
|
16.1 |
The covenants and post-termination restrictions contained in Schedule 2 form part of your contract of employment with the Company. These covenants and post-termination restrictions are of a continuing nature and shall remain in full
force and effect notwithstanding the termination of employment. You agree and accept that you shall adhere with the contents of Schedule 2 and, if you fail to comply with the contents of Schedule 2, the covenants and post-termination
restrictions may be enforced against you.
|
17. |
HEALTH AND SAFETY
|
17.1 |
The Company is under a duty to ensure, so far as possible, the health and safety and welfare at work of all employees and customers. You are expected to take reasonable care for the health and safety of yourself and all other people who
may be affected by your acts or omissions at work and to co-operate with the Company, so far as is necessary, to perform any duty or comply with any requirement imposed by any relevant law.
|
17.2 |
It is your duty to co-operate fully with the health and safety policy by all means including:
|
17.2.1 |
performing your duties safely and efficiently;
|
17.2.2 |
not doing anything which does, or might, injure any other person, or expose any other person to risk.
|
18. |
DISCIPLINARY AND GRIEVANCE PROCEDURES
|
18.1 |
You are subject to the Company's disciplinary and grievance procedures. These procedures do not form part of your contract of employment.
|
18.2 |
If you want to raise a grievance, you may apply in writing to your line manager (or if your grievance relates to your line manager, a more senior manager within the Company) in accordance with the Company's grievance procedure.
|
18.3 |
The Company may suspend you from any or all of your duties for no longer than is necessary to investigate any disciplinary matter involving you or so long as is otherwise reasonable while any disciplinary procedure against you is
outstanding.
|
18.4 |
During any period of suspension:
|
18.4.1 |
you shall continue to receive your basic salary and all contractual benefits in the usual way and subject to the terms of any benefit arrangement;
|
18.4.2 |
you shall remain an employee of the Company and bound by the terms of this agreement;
|
18.4.3 |
you shall ensure that your line manager knows where you will be and how you can be contacted during each working day (except during any periods taken as holiday in the usual way);
|
18.4.4 |
the Company may exclude you from your place of work or any other premises of the Company or any Associated Company; and
|
18.4.5 |
the Company may require you not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company
or any Associated Company.
|
19. |
AMALGAMATION
|
20. |
COLLECTIVE AGREEMENT
|
21. |
DATA PROTECTION
|
21.1 |
You and the Company acknowledge that they have obligations under the Data Protection Legislation.
|
21.2 |
The Company has published separate information to you in relation to its compliance with the Data Protection Legislation. To the extent applicable, you will comply with any obligations that you have or may have under the Data Protection
Legislation. This clause is in addition to and does not relieve, remove, replace or fetter, any obligations owed by either you or the Company under the Data Protection Legislation.
|
21.3 |
For the purposes of this clause, “Data Protection Legislation” means (i) unless and until the GDPR is no longer directly applicable in the UK, the General Data Protection Regulation ((EU) 2016/679) and any national implementing laws,
regulations and secondary legislation, as amended or updated from time to time, in the UK (including the Data Protection Act 2018) and then (ii) any successor legislation to the GDPR or the Data Protection Act 2018.
|
21.4 |
You acknowledge that you have received from the Company a copy of its Internal Privacy Policy and Data Protection Policy. You confirm that you have read and understood the Internal Privacy Notice and Data Protection Policy and will agree
to adhere to the Company’s data protection rules, policies and procedures as amended from time to time.
|
22. |
CHANGES TO TERMS OF EMPLOYMENT
|
23. |
INTERPRETATION
|
23.1 |
The following expressions have the following meanings: -
|
"Confidential Information"
|
any confidential information of the Company which may be known to or come to the knowledge of you by reason of your employment whether before, during or after the signing of this Agreement,
including without limitation:
|
i) |
the business dealings or affairs or prospective business dealings or affairs of the Company or any Associated Company or any person with whom the Company or any Associated Company has business dealings; | |
ii) |
the Materials and Intellectual Property in the Materials that are owned, licensed or used by the Company or any Associated Company; | |
iii) |
the developments, plans, blueprints, structure, layout, designs, make up, and drawings of the Company’s or any Associated Company’s products or devices or potential products or devices; |
iv) |
the processes, methods, testing, implementation and production of the Company’s or any Associated Company’s products or devices; | |
v) |
the trade secrets, ideas, knowledge and knowhow in relation to the Company’s or any Associated Company or its or their processes, methods, testing, implementation, production, products, devices or potential products or devices, | |
vi) |
all research activities, inventions, creative briefs, computer programmes, secret processes, designs and formulae undertaken, commissioned or produced by, or on behalf of, the Company or any Associated Company; | |
vii) |
the finances of the Company or any Associated Company, customer lists, trading details, price lists, details of customers and prospective customers, the terms of trading with suppliers, agents, distributors, contractors, licensors or licensees of the Company or any Associated Company; | |
viii) |
details of marketing development, pre-selling or other exploitation of any Intellectual Property of the Company or any Associated Company which has taken place, any proposed options or agreements to purchase, licence or otherwise exploit any Intellectual Property of the Company or any Associated Company, any Intellectual Property which is under consideration for development by the Company or any Associated Company and details of any advertising, marketing or promotional campaign which the Company or any Associated Company is to conduct and information relating to expansion plans, business strategy, marketing plans and sales forecasts of the Company or any Associated Company; | |
ix) |
any information obtained by you in the course of your employment which is confidential; or | |
x) |
any information designated by the Company as confidential. |
“Employment Inventions”
|
means any Invention which is made wholly or partially by you at any time during the course of your employment with the Company (whether or not during working hours or using Company premises
or resources, and whether or not recorded in material form).
|
“Employment IPRs”
|
means Intellectual Property Rights created by you in the course of your employment with the Company (whether or not during working hours or using Company premises or resources).
|
23.2 |
Words importing the singular include the plural and vice versa and words importing gender include both genders.
|
23.3 |
References to any provisions or any statute shall be deemed to include a reference to all and every statutory amendment, modification, re-enactment and extension in force on or after the date of this Agreement.
|
23.4 |
Save where otherwise appears, reference to a clause or schedule shall be deemed to be a reference to a clause or schedule of or to this Agreement.
|
23.5 |
Headings to clauses are for the convenience of reference only and shall not affect the meaning or construction of anything contained in this Agreement.
|
Signed by Director for and on behalf of SatixFy UK LIMITED:
|
)
)
)
|
/s/ Menachem Burko
Menachem Burko
Director
|
SIGNED by
Nir Barkan
|
)
)
)
|
/s/ Nir Barkan
|
1) |
SatixFy UK Limited of Spectrum Point, 279 Farnborough Road, Farnborough, Hampshire, GU14 7LS, United Kingdom (“the Company")
|
2)
|
Nir Barkan, of Chelsea Court, 17 Melville Place, London, N1 8 NE (“you")
|
1. |
You acknowledge and agree that the terms defined within this Deed shall have the same meaning as defined within your contract of employment with the Company to which this Deed is attached as Schedule 1.
|
2. |
You acknowledge that all Employment IPRs, Employment Inventions and all materials embodying them shall automatically belong to the Company to the fullest extent permitted by law. To the extent that they do not vest in the Company
automatically, you hold them on trust for the Company.
|
3. |
You acknowledge that, because of the nature of your duties and the particular responsibilities arising from the nature of your duties, you have, and shall have at all times while you are employed by the Company, a special obligation to
further the interests of the Company.
|
4. |
To the extent that legal title in and to any Employment IPRs or Employment Inventions does not vest in the Company by virtue of clause 3, you agree, immediately on creation of such rights and Inventions, to offer to the Company in
writing a right of first refusal to acquire them on arm's length terms to be agreed between the parties. If the parties cannot agree on such terms within 30 days of the Company receiving the offer, the Company shall refer the dispute for
determination to an expert who shall be appointed by the President of the Chartered Institute of Arbitrators. The expert's decisions shall be final and binding on the parties in the absence of manifest error, and the costs of arbitration
shall be borne equally by the parties. The parties will be entitled to make submissions to the expert and will provide (or procure that others provide) the expert with such assistance and documents as the expert reasonably requires for the
purpose of reaching a decision. You agree that the provisions of this clause shall apply to all Employment IPRs and Employment Inventions offered to the Company under this clause 3 until such time as the Company has agreed in writing that
you may offer them for sale to a third party.
|
5. |
You agree:
|
a. |
to give the Company full written details of all Employment Inventions promptly on their creation;
|
b. |
at the Company's request and in any event on the termination of his employment to give to the Company all originals and copies of correspondence, documents, papers and records on all media which record or relate to any of the Employment
IPRs;
|
c. |
not to attempt to register any Employment IPR nor patent any Employment Invention unless requested to do so by the Company; and
|
d. |
to keep confidential each Employment Invention unless the Company has consented in writing to its disclosure.
|
6. |
You waive all present and future moral rights which arise under the Copyright Designs and Patents Act 1988, and all similar rights in other jurisdictions relating to any copyright which forms part of the Employment IPRs, and agree not to
support, maintain or permit any claim for infringement of moral rights in such copyright works.
|
7. |
You acknowledge that, except as provided by law, no further remuneration or compensation other than that provided for in this agreement is or may become due to you in respect of your compliance with this clause. This clause is without
prejudice to your rights under the Patents Act 1977.
|
8. |
You undertake to use your best endeavours to execute all documents and do all acts both during and after your employment by the Company as may, in the opinion of the Company, be necessary or desirable to vest the Employment IPRs in the
Company, to register them in the name of the Company and to protect and maintain the Employment IPRs and the Employment Inventions. Such documents may, at the Company's request, include waivers of all and any statutory moral rights relating
to any copyright works which form part of the Employment IPRs. The Company agrees to reimburse your reasonable expenses of complying with this clause 7.
|
9. |
You agree to give all necessary assistance to the Company to enable it to enforce its Intellectual Property Rights against third parties, to defend claims for infringement of third party Intellectual Property Rights and to apply for
registration of Intellectual Property Rights, where appropriate throughout the world, and for the full term of those rights.
|
10. |
You hereby irrevocably appoint the Company to be your attorney in your name and on your behalf to execute documents, use your name and do all things which are necessary or desirable for the Company to obtain for itself or its nominee the
full benefit of this clause.
|
Executed as a deed by SatixFy UK LIMITED acting by a director in the presence of:
|
)
)
)
|
/s/ Menachem Burko
Menachem Burko
Director
|
Witness signature
Name
Address
Occupation:
|
/s/ Vasu Narayanachar
Vasu Narayanachar
____________________________________________
HR Manager
|
SIGNED as a DEED by
Nir Barkan
in the presence of:
|
)
)
)
|
/s/ Nir Barkan
Nir Barkan
|
Witness signature
Name
Address
Occupation:
|
/s/ Itzik Ben Bassat
Itzik Ben Bassat
____________________________________________
COO, SatixFy
|
1. |
You and the Company agree and acknowledge that it is reasonable and necessary for the protection of the goodwill and trade connections, trade secret or confidential information or other legitimate proprietary interest of the Company that
you should be restrained in the terms of the restrictions set out below.
|
2. |
In relation to the restrictions set out in this clause:
|
(i) |
application specific integrated circuits or chips; or
|
(ii) |
radio frequency integrated circuits or chips;
|
(i)
|
who or which at any time in the Relevant Period, was a prospective customer of the Company, to whom or which the Company made a
proposal to provide services or products directly to the prospective customer in the Relevant Period; and
|
(ii)
|
for the purpose of a Relevant Business, provided that this definition shall apply only to persons, companies or other
organisations, with whom you have or had dealings in preparing or submitting the proposal to provide services or products at any time in the Relevant Period, or about to whom or which you obtained confidential information as a result of
your employment.
|
3. |
You will not Directly or Indirectly for the Restriction Period be involved or engaged in in any Capacity in any Relevant Business so as to compete or intend to compete with the Company or any Associated Company.
|
4. |
You will not Directly or Indirectly for the Restriction Period, solicit or seek to entice away from the Company or any Associated Company the business or trade of a Relevant Customer or Relevant Prospective Customer with the intention of
supplying or providing services or products to that Relevant Customer or Relevant Prospective Customer so as to compete or seek to compete with any Relevant Business.
|
5. |
You will not Directly or Indirectly, for the Restriction Period, in competition with any Relevant Business deal with or supply or provide services or products or accept business from any Relevant Customer or Relevant Prospective
Customer.
|
6. |
You will not Directly or Indirectly, for the Restriction Period, for your benefit or on behalf of any business which is in competition with any Relevant Business, offer employment or engagement to a Relevant Employee of the Company or
any Associated Company, whether or not this would be a breach of contract on the part of that Relevant Employee.
|
7. |
You will not Directly or Indirectly, for the Restriction Period, for your benefit or on behalf of any business which is in competition with any Relevant Business, persuade or encourage or attempt to persuade or encourage a Relevant
Employee to leave the employment of the Company or any Associated Company, whether or not this would be a breach of contract on the part of that Relevant Employee.
|
8. |
You will not Directly or Indirectly, for the Restriction Period, accept employment or work with or for any Relevant Customer or Relevant Prospective Customer in competition with any Relevant Business.
|
9. |
You will not Directly or Indirectly, for the Restriction Period, interfere with, undermine, attempt to affect or damage any supply agreement or other arrangement between the Company or any Associated Company and any Relevant Supplier so
as to seek to compete with any Relevant Business.
|
10. |
Following termination of your employment, you shall not in any way hold yourself out or permit yourself to be held out as continuing to be connected with the business of the Company or any Associated Company.
|
11. |
You acknowledge and agree that each of the restrictions contained in the above sub clauses are intended to be separate and severable. If any of the restrictions are held to be void, this will not affect the enforceability of the
remaining restrictions, and if any restriction is held to be void but would be valid if part of the wording in the restriction was deleted such restriction will apply with such deletion as may be necessary to make it valid and effective.
|
12. |
None of the restrictions in this Schedule 2 shall prevent you from:
|
a. |
holding an investment by way of shares, or other securities, of less than 5% of the total issued share capital of any company (whether or not it is listed or dealt in on a recognised stock exchange);
|
b. |
being engaged or concerned in any business concern insofar as your duties or work shall relate solely to geographical areas where the business concern is not in competition with any Relevant Business; or
|
c. |
being engaged or concerned in any business concern, provided that your duties or work shall relate solely to services or activities of a kind with which you were not concerned to a material extent in the Relevant Period.
|
13. |
If your employment is transferred to any firm, company, person, entity or another Group Company (the "New Employer") pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, you will, if required, enter into
an agreement with the New Employer containing post-termination restrictions corresponding to those restrictions in this Schedule 2, protecting the confidential information, trade secrets and business connections of the New Employer.
|
14. |
You will, at the Company’s request and expense, enter into a separate agreement with any Group Company in which he agrees to be bound by restrictions corresponding to those restrictions in this Schedule 2 (or such of those restrictions
as may be appropriate) in relation to that Group Company.
|
1.
|
I have reviewed this annual report on Form 20–F of SatixFy Communications Ltd.;
|
2.
|
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual
report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
|
5.
|
The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the company’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over
financial reporting.
|
Date: March 29, 2024
|
![]() |
|
Nir Barkan
|
|
Acting Chief Executive Officer
|
1.
|
I have reviewed this annual report on Form 20–F of SatixFy Communications Ltd.;
|
2.
|
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual
report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
|
5.
|
The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the company’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over
financial reporting.
|
Date: March 29, 2024
|
![]() |
|
Oren Harari
|
|
Interim Chief Financial Officer
|
Date: March 29, 2024
|
![]() |
|
Nir Barkan
|
|
Acting Chief Executive Officer
|
Date: March 29, 2024
|
![]() |
|
Oren Harari
|
|
Interim Chief Financial Officer
|
/s/ Ziv Haft
Certified Public Accountants (Isr.)
BDO Member Firm
|
1.
|
Definitions. For the purposes of this Policy, the following terms shall have the meanings set forth below. .
|
2. |
Recoupment of Erroneously Awarded Compensation.
|
8. |
Miscellaneous.
|